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Abstract
Human immunodeficiency virus (HIV) infection causes profound impairment of CD4+ T cell immunity.
Anti-retroviral therapy (ART) restores CD4+ T cell responses to common antigens, but HIV-specific
responses remain deficient. The immunization of chronically HIV infected, ART treated subjects also leads to
poor HIV-specific CD4+ T cell responses. The mechanisms are not fully understood. In this thesis, I
demonstrate that HIV envelope glycoprotein (Env), when delivered in the form of a vaccine or when present
on free viral particles, suppresses antigen-stimulated CD4+ T cell proliferation. I investigate the potential
involvement of human T regulatory cells (Treg) using an in vitro model system. I show that Env exposure
neither changes the frequency nor the suppressive activity of Treg cells in human PBMC, and that Env-
induced suppression of CD4+ T cell proliferation is independent of Tregs. The studies of HIV-induced
inhibition of CD4+ T cell immunity were then moved to an in vivo model to determine physiological
significance. A macaque model of HIV-infected individuals treated with ART during chronic infection was
used to study the effect of SIV antigen stimulation in lymph nodes early after immunization. CMV
seropositive rhesus macaques were infected with pathogenic SIVmac251 and after 4 months, treated with
D4T and PMPA for viral control and immune reconstitution. I studied the immune and viral responses to SIV
and CMV antigen immunization in draining lymph nodes. Animals were immunized with both SIV gag and
CMV pp65 encoding plasmids in both arms and legs, which allowed draining lymph nodes for each antigen to
be obtained at the same time, thus allowing direct comparisons of the effect of each antigen stimulation in the
same animal. I observed that both SIV and CMV antigen immunizations stimulated antigen-specific T cell
responses in draining lymph nodes. The CMV-specific responses were found in the periphery for 50 days post-
immunization, while the SIV-specific responses transiently appeared. The SIV antigen stimulation also
induced transient SIV viral replication in the draining lymph nodes, suggesting a mechanism for the early loss
and poor HIV-specific CD4+ T cell response observed in HIV-infected progressors.
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ABSTRACT 
HIV IMMUNOPATHOGENESIS: INHIBITION OF CD4+ T  
CELL ACTIVATION 
Haitao Hu 
Dissertation Supervisor: Drew Weissman, MD, PhD 
Human immunodeficiency virus (HIV) infection causes profound impairment of CD4+ T 
cell immunity. Anti-retroviral therapy (ART) restores CD4+ T cell responses to common 
antigens, but HIV-specific responses remain deficient. The immunization of chronically 
HIV infected, ART treated subjects also leads to poor HIV-specific CD4+ T cell 
responses. The mechanisms are not fully understood. In this thesis, I demonstrate that 
HIV envelope glycoprotein (Env), when delivered in the form of a vaccine or when 
present on free viral particles, suppresses antigen-stimulated CD4+ T cell proliferation. I 
investigate the potential involvement of human T regulatory cells (Treg) using an in vitro 
model system. I show that Env exposure neither changes the frequency nor the 
suppressive activity of Treg cells in human PBMC, and that Env-induced suppression of 
CD4+ T cell proliferation is independent of Tregs. The studies of HIV-induced inhibition 
of CD4+ T cell immunity were then moved to an in vivo model to determine 
physiological significance. A macaque model of HIV-infected individuals treated with 
ART during chronic infection was used to study the effect of SIV antigen stimulation in 
lymph nodes early after immunization. CMV seropositive rhesus macaques were infected 
with pathogenic SIVmac251 and after 4 months, treated with D4T and PMPA for viral 
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control and immune reconstitution. I studied the immune and viral responses to SIV and 
CMV antigen immunization in draining lymph nodes. Animals were immunized with 
both SIV gag and CMV pp65 encoding plasmids in both arms and legs, which allowed 
draining lymph nodes for each antigen to be obtained at the same time, thus allowing 
direct comparisons of the effect of each antigen stimulation in the same animal.  I 
observed that both SIV and CMV antigen immunizations stimulated antigen-specific T 
cell responses in draining lymph nodes. The CMV-specific responses were found in the 
periphery for 50 days post-immunization, while the SIV-specific responses transiently 
appeared. The SIV antigen stimulation also induced transient SIV viral replication in the 
draining lymph nodes, suggesting a mechanism for the early loss and poor HIV-specific 
CD4+ T cell response observed in HIV-infected progressors. 
 
 
 
 
 
 
 
 
 
 
 
	   vi	   	   	  
Table of Contents 
Acknowledgements .……………………………………………………………………. iii 
Abstract .………………………………………………………………………….……...iv 
Table of Contents .……………………………………………………………………….vi 
List of Figures .…………………………………………………………………………. x 
List of Tables ....................................................................................................................xi 
CHAPTER 1  
Introduction .…………………………………………………………………………... 1 
HIV and its global epidemic ………………………………………………...……. 1 
Clinical course of HIV infection …………………………………………………. 4 
Impairment of CD4+ T cell immunity in HIV.……………………………………. 6 
HIV Envelope protein and inhibition of CD4+ T cell response ….……………..... 7 
T regulatory cells and HIV...................................................................................... 10 
Immunization and T cell immune dysfunction in chronic HIV infection during 
HAART  ……………………………………………………………………..……13 
         Aims of thesis ………………………………………………………………..…... 16 
 
CHAPTER 2 
HIV Envelope Suppresses CD4+ T Cell Activation Independent of T Regulatory 
Cells ………………………………………………………………………………….… 17 
Introduction ………………………………………………………………………..…… 17 
Materials and Methods …………………………………………………………….…… 19 
	   vii	   	   	  
Cells and HIV-1……………………………………………………………...……19 
         Plasmid constructs and RNA synthesis ……………………….…………………. 20 
DC infection with vaccinia virus ………………………………………………… 20 
        Exposure of CD4+ T cells to Env and CD4+ T cell proliferation ……….…………20 
        Detection of apoptosis and activation in CD4+ T cells exposed to Env ……..…… 21 
        Detection of phosphorylation of signaling molecules in CD4+ T cells ………...… 22 
        CD25+ cell depletion and T cell proliferation assay ……………………………… 22 
        Treg sorting and suppression culture …………………………………………...… 23 
        Treg analyses ………………………………………………………………...…… 23 
        IL-10 and TGF-β ELISA ……………………………………………………….… 24 
        Statistics ……………………………………………………………………...…… 24 
Results ………………………………………………………………………………..… 25 
Env expressed on free virions suppresses CD4+ T cell proliferation …………...… 25 
DCs expressing Env suppress CD4+ T-cell proliferation ……………………….… 30 
       Neither apoptosis nor IL-2-dependent anergy mediate CD4+ T cell suppression .....32 
CD4+ T cells activated in the presence of Env phosphorylate AKT, MAPK, and 
STAT5a, but fail to completely up-regulate activation markers ………………….. 35 
Env expressed on free virions suppresses CD4+ T cell proliferation ……………... 37 
CD25+ Treg cells are not required for Env induced suppression ………………..... 40 
Effect of Env on frequency of CD4+, CD25+, FoxP3+ cells inPBMC …………..... 42 
IL-10 and TGF-β production in Env exposed PBMC ………………………………..... 45 
Env does not enhance suppressive activity of CD4+, CD25+, CD127- T cells .....… 46 
	   viii	   	   	  
Discussion …………………………………………………………………………....… 51	  
	  
CHAPTER 3	  
In vivo analysis of immune and viral responses in retroviral suppressed SIV infected 
rhesus macaques ………………………………………………………………....…… 58 
 
Introduction ……………………………………………………………………......…… 58 
Materials and Methods …………………………………………………………….....… 60 
Ethics Statement ……………………………………………………………….... 60 
Immunogens …………………………………………………………………...... 60	  
Infection of rhesus macaques and overview of study ………………………….... 60 
Measurement of peripheral viral load and CD4+ T cell counts ………………..... 61 
          PBMC isolation and LN biopsy ………………………………………………..... 61 
In vitro stimulation …………………………………………………………….... 62 
Cell staining …………………………………………………………………....... 62	  
Flow cytometric analysis ………………………………………………………... 63 
RNA extraction and quantitative PCR ………………………………………...... 64 
Statistics ………………………………………………………………………..... 65 
Results  ………………………………………………………………………………..... 66 
PART 1: Infection and immunization of rhesus macaques and study overview ... 66 
PART 2. Establishment of chronically SIV-infected rhesus macaque with retroviral 
suppression and CD4+ T cell recovery by ART ……………………………....… 67 
	   ix	   	   	  
PART 3. Immunization induced immunologic responses in draining LNs …….. 69	  
3-1: Immunization-induced immune activation in draining LNs …….....… 69	  
3-2: SIV immunization induced SIV gag-specific T cell responses in LN .. 71	  
3-3: CMV immunization induced CMV pp65-specific T cell responses in LN           	  
      …………………………………………………......................………... 75	  
PART 4. SIV- and CMV-specific T cell responses in peripheral blood ……........77	  
4-1: Tetramer staining for the number of SIV-specific CD8+ T cells in 
periphery ………………………………………………………….......…… 77	  
4-2: SIV- and CMV-specific T cell response in PBMC ………………...… 79	  
4-3. T cell subsets that mediate SIV- and CMV-specific T cell responses in  
PBMC ……………………………………………………………………... 81	  
                   4-4. Increased PD-1 expression in SIV-specific CD8+ T cells …………..... 83	  
PART 5. Immunization induced virologic responses in draining LNs 
5-1: SIV immunization selectively stimulates transient activation of viral 
replication in draining LNs ……………………………………………....... 85 
5-2. No increased viral loads were observed in periphery ……….......…… 88 
Discussion …………………………………………………………………........……… 89 
CHAPTER 4	  
Thesis conclusions and implications ………………………………………......….…… 95	  
Ongoing experiments and future directions ……………………………………........… 97 
CHAPTER 5 	  
References ………………………………………………………………………........... 99 
	   x	   	   	  
List of Figures 
Figure 1.1. Schematic illustration of HIV replication cycle in an infected cell ……….... 2 
Figure 1.2. Alternative splicing of the HIV-1 primary transcript ………………….....… 4 
Figure 1.3. Natural course of HIV infection …………………………………….....…… 5 
Figure 2.1. HIV Env induces suppression of anti-CD3 stimulated CD4+ T cell 
proliferation ……………………………………………………………..............……… 28 
Figure 2.2. DCs expressing Env and presenting antigen suppress CD4+ T cell 
proliferation ………………………………………………………………..........……… 32 
Figure 2.3. Neither apoptosis nor IL-2–dependent anergy mediate Env-induced CD4+ T 
cell suppression ………………………………………………………………........…… 34 
Figure 2.4. CD4+ T cells activated in the presence of Env phosphorylate AKT, p38 
MAPK, and STAT5a but fail to up-regulate the activation markers CD69, CD25, and 
HLA-DR ……………………………………………………………..........…………… 36 
Figure 2.5. HIV Env present on free virions induces suppression of anti-CD3 stimulated 
CD4+ T cell proliferation through CD4 binding ……………………………......……… 39 
Figure 2.6. CD25+ Treg cells are not required for Env-induced suppression of 
proliferation …………………………………………………………………..........…… 41 
Figure 2.7. Effect of Env delivered by cell surface expression or on virions on FoxP3+, 
CD25+, Treg cells in unstimulated and stimulated PBMC ……………………......…… 44 
Figure 2.8. Effect of Env exposure on IL-10 production …………………………….… 46 
Figure 2.9. Endogenously present or activation induced (plus FoxP3, CD25) FoxP3+ Treg 
cell suppressive activity is not modulated by Env. ……………………………......…… 49 
 
Figure 3.1. Experimental protocol for infection and immunization of rhesus macaques..66 
Figure 3.2. Summary of viral loads and peripheral CD4+ T cell counts in rhesus macaques  
………………………………………………………………………………...................68 
Figure 3.3.1. Total IFN-γ mRNA expression in draining LNs ………………………….70	  
Figure 3.3.2. SIV immunization induced SIV gag-specific T cell responses in Day-3 LN 
………………………………………………………………………………................... 72 
Figure 3.3.3. CMV immunization induced CMV pp65-specific T cell responses in Day-5 
LN ………………………………………………………………………………....…… 76 
Figure 3.4.1. SIV gag Mamu A*01 tetramer staining of PBMC …………………….… 78 
Figure 3.4.2. SIV- and CMV-specific T cell responses in peripheral blood during 
immunization ……………………………………………………………………...…… 80 
Figure 3.4.3. Analysis for T cell subsets mediating the antigen-specific T cell responses 
in PBMC …………………………………………………………………………......… 82	  
Figure 3.4.4. PD-1 expression on SIV-specific and non-SIV specific CD8+ T cells in 
macaque PBMC ………………………………………………………………...……… 84	  
Figure 3.5. Quantitation of multiple SIV viral RNAs in LNs ……………………......... 86 
	   xi	   	   	  
List of Tables 
Table 1. Statistical analysis of suppression of CD4+ T cell proliferation by Env …...… 30 
Table 2. Effect of monomeric gp120 on CD4+ T cell proliferation …………….....…… 30 
Table 3. Effects of HIV Env on activation marker expression …………………....…… 37 
Table 4. Primers and probes for real-time PCR quantitation of SIV viral RNAs …....… 65 
Table 5. Viral loads in periphery during antigen immunization …………………......… 88 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   1	   	   	  
CHAPTER 1 
Introduction 
HIV and the global epidemic 
              Human immunodeficiency virus (HIV) is a lentivirus that causes acquired 
immunodeficiency syndrome (AIDS) in humans 48, 162. As of December 2008, between 
31.1 million and 35.8 million people were believed to be living with HIV. The number of 
people newly infected in 2008 was estimated to be 2.7 million and approximately 2 
million people died from HIV infection (AIDS epidemic update 2009, UNAIDS).  
 
               HIV is composed of two copies of single-stranded genomic RNA that are 
enclosed by capsid and contain nine genes encoding 19 proteins. The HIV replication 
cycle is summarized in Figure 1.1144. First, the glycoprotein complex present on the 
surface of virus, known as Env or gp160, enables the virus to attach to target cells to 
initiate entry and infection 27. Entry of HIV into the host cell depends on the interaction 
between the viral envelope and CD4 plus a co-receptor (generally either CCR5 or 
CXCR4) on the surface of target cells. Binding of gp120 to CD4 leads to a 
conformational change in Env and the subsequent exposure of the co-receptor binding 
site, which allows gp120 to interact with a target chemokine receptor to mediate fusion 
and entry 28, 169.  
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Figure 1.1 
 
Figure 1.1. Schematic illustration of HIV replication cycle in an infected cell.  LTR: 
long terminal repeat; RT: reverse transcriptase 144 
           
             The viral RNA genome is reverse transcribed shortly after the virus enters the 
cell and the preintegration complex is transported into the cell nucleus and integrates into 
host cell’s genome. Infection of CD4+ T cells has 2 main outcomes, lytic and latent. In 
latent infection, the integrated viral DNA may lie “dormant” in resting memory cells. 
When such cells become activated, the integrated DNA provirus starts viral gene 
expression and viral replication. The HIV genome contains multiple splice sites, resulting 
in alternatively spliced mRNAs. They can be divided into three groups: unspliced, singly 
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spliced, and doubly spliced (Figure 1.2). In brief, the proviral DNA is first transcribed 
into a primary viral RNA transcript, which is about 9 kb in length and serves as both 
genomic RNA for progeny virus and the unspliced viral mRNA encoding viral Gag and 
Gag-Pol proteins. Alternative retention or splicing of the primary transcript and nuclear 
export of the unspliced transcript are well regulated. During the early phase of viral 
replication, two doubly spliced viral transcripts are produced and exported into 
cytoplasm, where they are translated into the regulatory and accessory proteins Tat, Rev 
and Nef.  These viral proteins regulate subsequent viral gene expression and cellular 
function. As the newly generated Rev proteins accumulate in the nucleus, they bind to the 
transcribed viral mRNA and facilitate the export of singly spliced and unspliced mRNAs, 
which encode the viral structural proteins Env and Gag. The full-length unspliced viral 
genomic RNA binds to Gag polyproteins which traffic to the cell membrane for viral 
assembly. Among the numerous cellular factors reported to be involved in HIV assembly 
and budding, the ESCRT cellular machinery (Endosomal Sorting Complex Required for 
Transport), which was initially discovered to be important for the biogenesis of 
multivesicular bodies (MVB), recruits the Gag p6 domain and plays a key role in 
formation and release of new particles. It is currently thought that the resulting late-
budding structure is released by the cellular ESCRT machinery severing the membrane 
tether connecting it to the producer cell 13, 104.   
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Figure 1.2 
 
Figure 1.2. Schematic illustration of alternative splicing of the HIV-1 primary 
transcript.  (i) is unspliced, (ii) to (iv) are singly spliced, (v) and (vi) are doubly spliced.  
The resulting mRNA (i), (iv) and (vi) are bicistronic.  The star "*" indicates the location 
of the initiation codon (AUG).  (From Web-book: http://www.web-books.com/) 
Clinical course of HIV infection 
            The clinical course of HIV infection generally includes three phases or stages: 1) 
acute infection; 2) chronic or latent infection; and 3) AIDS-defining illness. Such a 
course of infection is characteristic of the so-called typical progressor who represents the 
majority of HIV-infected individuals (Figure 1.3). Three major clinical parameters are 
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associated with HIV disease progression: viral load, immune activation, and peripheral 
CD4+ T cell number. In acute infection, rapid viral replication occurs leading to acute 
viremia, followed by a massive depletion of CD4+ T cells 33, 124. Activation of CD8+ T 
cells is then detected and believed to significantly control acute viral replication ???. The 
disease transition from primary infection to the clinical latent stage is characterized by 
downregulation of viremia and resolution of symptoms, if present. A set point for viral 
load is usually formed in this stage. HIV disease is still active with persistent replication 
of virus and progressive loss of CD4+ T cells. Finally, when CD4+ T cell numbers decline 
below a critical level cellular immunity drops to a point leading to infections with a 
variety of opportunistic pathogens defined as AIDS 51, 117. 	  
Figure 1.3	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Figure 1.3. Natural course of HIV infection. The diagram demonstrates the relationship 
between viral load and peripheral CD4+ T cell count.  
 
Impairment of CD4+ T cell immunity in HIV 
          CD4+ T cells play a central role in maintaining effective cellular and humoral 
immune responses by providing help to CD8+ T cells, B cells and innate effectors 22. In 
HIV infection, the number of circulating CD4+ T cells is commonly used as a measure of 
global “immune competence” and provides a predictor for the immediate risk of 
opportunistic infections 101. The importance of cellular immunity in HIV infection has 
been identified in many studies, even though the specific protective immune correlates 
have not been fully elucidated. Enhanced cellular immunity towards HIV has been linked 
with better control of viral replication in patients who show slow or delayed disease 
progression 67, 106, 118.  
 
           However, one of the key features for HIV infection is the profound impairment of 
CD4+ T cell immunity, attributed both to the massive loss of CD4+ T cells mediated by 
direct viral infection during early infection and the subsequent progressive loss of CD4+ 
T cells during the chronic stage 47, 125.  In addition to cell depletion, functional 
abnormalities of CD4+ T cells also contribute significantly to the impaired CD4+ T cell 
immunity in HIV. T cells from HIV-infected individuals showed reduced proliferation 
following stimulation with antigens or mitogens in vitro34. Diminished expression of IL-2 
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is readily demonstrated in these cells and may be related to the proliferation defects 139. 
Furthermore, a sequential loss of immune responsiveness to recall antigens, followed by 
alloantigens and then mitogens has been described for CD4+ T cells from HIV-infected 
individuals 34. Further studies using TCR stimulation to characterize the proliferation 
defects in CD4+ T cells indicate that such defects are associated with early-phase cell-
cycle arrest 140 and are commonly observed in patients with sustained CD4+ T cell loss 
141. Since CD4+ T cells play a key role in regulating antibody responses, CTL responses 
and other innate effectors, the loss of these cells constitutes a major impairment in 
immune capacity in HIV infection.  
 
HIV Envelope protein and inhibition of CD4+ T cell response 
          As described above, HIV infection causes profound CD4+ T cell impairment 
leading to immune suppression and the development of AIDS (49). Mechanisms have 
been suggested for this including direct cytopathic effects of HIV, accumulation of 
unintegrated viral DNA or toxic viral proteins, virus-induced changes in target cell 
membrane permeability, and apoptosis of HIV-infected CD4+ T cells (50). Other 
proposed mechanisms include lysis of CD4+ T cells by cytolytic T cells and tryptophan 
depletion by indolamine 2,3-dioxygenase (51, 52). However, in many patients only a 
small fraction of CD4+ T cells appear to be infected and the degree of cell loss greatly 
exceeds the number of infected cells, indicating that virus-induced bystander dysfunction 
plays a role in CD4+ T cell deficiency.  
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             Among the HIV proteins, Env, expressed on the surface of free virions and 
infected cells, is a potent immune inhibitory molecule and has been demonstrated to play 
a predominant role in suppressing CD4+ T cells by multiple mechanisms (61, 62, 63). 
CD4 is a transmembrane glycoprotein that plays an important role in T helper cell 
function by interacting with MHC class II during T cell activation 73. However, it has 
been shown that cross-ligation of CD4 molecules prior to TCR stimulation primes the 
cells for apoptosis or a non-responsiveness state upon TCR activation 146,63. Env is a 
trimeric protein with each of its monomers possessing a CD4 and co-receptor binding 
site, and it has been demonstrated to produce a similar effect on CD4 ligation. Env 
multimers created in vitro with antibodies against monomeric gp120 subunits can 
mediate cross-linking of CD4 and/or co-receptor leading to signaling that causes aberrant 
activation of CD4+ T cells 10, 132. These observations from in vitro culture systems are 
consistent with the studies of HIV-infected patients demonstrating that similar 
interactions between Env on infected cells or virions can cause apoptosis of uninfected 
bystander CD4+ T cells, which occurs primarily in lymphoid tissues where antigen 
presentation and T cell activation occur 55.  A proposed hypothesis is that when 
bystander, uninfected HIV-specific CD4+ T cells have CD4 pre-ligated by Env, they 
undergo apoptosis after they are activated via TCR stimulation by the cognate antigen 
presenting cells (APCs) 37. For Env-induced apoptosis of bystander CD4+ T cells, 
multiple apoptotic pathways have been proposed. Ligation of CD4 receptor by Env prior 
to TCR stimulation leads to upregulation of Fas in CD4+ T cells, and the subsequent 
expression of Fas-L upon TCR activation thereby renders the T cells susceptible to 
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apoptosis by Fas-FasL pathway 146. Fas independent apoptosis and other death pathways, 
including tumor necrosis factor (TNF)-TRAIL pathway, have also been reported as 
mechanisms for Env-induced apoptosis 15, 58, 77, 113, 127.  In addition to apoptosis, lack of 
proliferation 132 and induction of IL-2 reversible anergy99 have also been suggested as 
forms of Env-induced inhibition of CD4+ T cells.   
 
            Although inhibition of CD4+ T cells by Env has been well established, the 
underlying mechanisms in terms of cellular signaling defects and the receptors utilization 
are not fully understood. CD4 binding has been shown to play a major role in mediating 
suppression in most studies 3, 19, 82. Treatment of CCR5Delta32 homozygote PBMCs with 
a CCR5-specific envelope induced apoptosis in T cells, demonstrating that CD4 could 
mediate suppression in the absence of co-receptor 7. In contrast, involvement of co-
receptor binding in Env-induced inhibition of CD4+ T cells was also reported. 
Stimulation of CCR5 by R5 Env triggers apoptosis of CD4+ T cells 4. Another study 
showed that bystander apoptosis of CD4+ T cells required direct contact with virions and 
Env/CXCR4 binding 71.  
 
             As previously mentioned, Env could deliver aberrant signals to CD4+ T cells 
through interaction with CD4 and/or coreceptors. Therefore, it is likely that T cell 
signaling cascades (TCR signaling and cytokine signaling) could be affected by Env as 
the molecular mechanisms for CD4+ T cell inhibition. Env-induced defects in JAK/STAT 
signaling pathways have been reported in multiple studies 89, 135. It was demonstrated that 
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exposure of CD4+ T cells to Env caused a failure of normal JAK-1 and JAK-3 activation 
and the unresponsiveness of STAT5a and STAT5b to IL-2 89. In addition, many studies 
have demonstrated defects in TCR signaling induced by Env. Binding activities of 
important transcription factors to target promoters, including NFAT, NFκB and AP-1, 
were observed to be significantly decreased in T cells with exposure to Env 75. Pre-
exposure of a T cell line to gp120 led to the inhibition of Lck activation in response to 
TCR/CD3 stimulation 109. In a study with primary human CD4+ T cells, pre-treatment of 
these cells with gp160 resulted in marked inhibition of tyrosine phosphorylation of p59 
(Fyn), PLC-gamma1 and ras activation, providing insight into the mechanism by which 
the Env may alter TCR/CD3-activation-induced signal transduction 145.  
 
            Collectively, the interference of TCR or cytokine signaling by Env is complex 
and the biochemical mechanisms are not fully understood. Env protein is a key 
component of an effective vaccine because it exclusively induces neutralizing antibodies 
72. Accordingly, understanding the mechanism for Env-induced inhibition is critical for 
designing effective Env-based HIV vaccine candidates and approaches.  
 
T regulatory cells (Treg) and HIV 
           The concept of suppressor T cells was first described by Gerson et al when they 
suggested that a population of T cells could suppress immune responses 61. Later on 
CD25 was identified as a surface marker for a population of suppressor T cells that could 
control autoimmune responses in mice, and these cells were termed regulatory T cells 
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(Treg). The discovery of the transcription factor FoxP3, which is highly expressed in both 
mouse and human Treg cells and is required for Treg cell function and development, has 
led to intensive studies of Treg biology in mouse models as well as for more reliable 
identification of Tregs in human 21, 29, 56, 95, 166.  
 
             Several subclasses of Treg cells have been identified. Tregs expressing FoxP3, 
CD4 and high levels of CD25 are termed natural regulatory T cells and are thought to 
primarily originate in the thymus, although studies have shown that these cells can be 
generated in the periphery from non-Treg cells under certain conditions 18. The other type 
of Treg cell is known as T regulatory 1 cells (Tr1) that express little or no FoxP3 but 
preferentially produce large amounts of IL-10 74. The TGF-ß-producing intraepithelial T 
cells in gut associated lymphoid tissues (GALT) are known as T helper 3 (Th3) with 
suppressive function 160. The current knowledge on Treg classification, phenotype and 
development is still limited and more research is needed. Treg cells can exert suppression 
by multiple mechanisms, although much remains to be elucidated 156, 172. Treg cells could 
induce suppression by direct cell-cell contact or soluble factors like IL-10 and/or TGF- ß 
31, 137. Whether Treg cells release IL-10 and thus exert contact-independent suppression is 
not clear, but it should be noted that IL-10 is primarily found in adaptive regulatory T 
cells, such as Tr1 cells, and it is indicated to play an important role in mediating 
suppression for these cells 156.  
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            Treg cells are traditionally believed to protect the host from autoimmune reactions 
by down-regulating autoimmune responses. However, there is accumulating evidence 
supporting an active role for Tregs in modulating immune responses directed to 
infectious agents, including HIV 2. Treg cells isolated from the peripheral blood and 
lymphoid tissues of HIV-infected patients have been demonstrated to maintain a 
suppressive activity on HIV-specific CD4+ and CD8+ T cell response 85, 86, 161. Both 
increased and decreased numbers of Treg cells have been reported in HIV infection, and 
a number of factors could influence the result, such as the tissues studied, the stage of 
infection, and the institution of ART. In addition, it becomes more complicated by the 
use of different Treg detection methods by different groups 5, 6, 49, 52, 85-87, 108, 112, 115, 149, 161. 
In studies using peripheral blood, both increased 1, 85, 161 and reduced 49, 115 frequencies of 
CD4+CD25+ Treg cells were reported, leading to two converse hypotheses that HIV 
drives expansion of Treg cells or HIV induces a selective loss of Treg cells. Subsequent 
studies using LN or gastrointestinal mucosal tissue demonstrated an increased frequency 
of suppressive Treg cells in HIV-infected patients, as detected by FoxP3 expression, 
supporting the hypothesis that Treg cells, rather than undergoing a selective loss induced 
by virus, accumulate at sites of viral expression, where they can exert suppression on Ag-
specific T cell activation 6, 52, 112. How HIV regulates the frequency and function of Treg 
cells during infection and how this regulation relates to HIV pathogenesis and host 
immunity, remains highly controversial. There is limited evidence, so far, demonstrating 
the direct interaction of Treg cells and HIV or its gene products. Human Treg isolated 
from healthy donors express the HIV coreceptor CCR5 and were reported to be the target 
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of HIV infection with high susceptibility 115. In contrast, it has been demonstrated that 
HIV increases Treg viability through Env-CD4 interaction, resulting in accumulation of 
Treg cells 112. Collectively, the regulation of Treg frequency and function by HIV and the 
physiological relevance in the context of HIV infection or vaccination are not fully 
understood. 
 
Immunization and immune dysfunction in chronic HIV/SIV infection during ART  
              The introduction of anti-retroviral therapy (ART) results in delayed disease 
progression and a remarkable decrease in AIDS related deaths. However, the current 
regimens for HIV treatment have major limitations. First, it fails to eradicate the virus. It 
has also been demonstrated that even during the most potent regimens of retroviral 
suppression, viral production continues, as detected by some ultrasensitive assays 43, 70, 
122. In addition, immune recovery subsequent to ART often appears to be partial and 
limited to certain T cell responses, and does not include HIV-specific CD4+ T cell 
responses 8, 83, 129.  
 
              Cell-mediated immunity is involved in controlling HIV replication and 
correlates with better control of disease progression, which provides a rationale for active 
immunization of chronically infected individuals to augment the existing T cell 
responses. A number of approaches attempting to stimulate cell-mediated responses by 
immunization have been studied in SIV-infected rhesus macaques during ART with 
mixed results reported regarding immunologic and virologic benefits 42, 57, 69, 96, 150, 157, 173. 
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Rhesus macaques with long-standing SIVmac251 infection were immunized three times 
with a poxvirus vector expressing the SIVmac structural and regulatory genes during 
ART. Following antiretroviral treatment interruption, the viral set point was significantly 
lower in immunized macaques than in control macaques 148. A strategy using autologous 
dendritic cells (DC) pulsed either with viral peptides or chemically inactivated virus, 
which could elicit strong immune control of the virus, has been tested in the SIV 
macaque model and demonstrated promising result 42, 96. Immunizations with DNA 
plasmids encoding multiple SIV antigens also offered long lasting immunologic and 
virologic benefits to SIVmac251 infected and ART treated macaques 157. In contrast to 
these promising results, very limited immunologic and virologic benefits by 
immunization in ART-treated, SIV infected macaques have also been reported. A study 
using the SIVmac239 model demonstrated that immunization with SIVmac239-derived 
Env, Gag/Pol, and Tat/Rev/Nef plasmids by in vivo electroporation elicited T-cell 
immune responses, but no control of SIVmac293 viremia 173.  Collectively, using various 
immunization strategies including DNA, poxvirus vectors, and antigen-pulsed DCs, SIV-
specific immune responses were evoked in SIV-infected rhesus macaques during ART. 
The virologic benefits of these immunizations after release of macaques from ART were 
variable from no control to temporal control or long-lasting control.  
 
              However, similar immunization (either vaccine or treatment interruption) for 
chronically HIV-infected, ART-treated humans has been disappointing, as no significant 
HIV-specific T cell responses were induced by immunization in this setting 66, which is 
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consistent with the observation that treatment with effective ART results in regained T 
cell responses to common antigens, but poor responses to HIV-specific antigens, 
suggesting the long-lived defects in the generation of HIV-specific CD4+ T cell immunity 
in HIV 8, 83, 129.  The mechanisms are not fully characterized or understood. Compared to 
peripheral blood, which has been commonly used to study the antigen-specific T cell 
responses to HIV/SIV infection or immunization, the secondary lymphoid tissues 
represent an important site where antigen presenation, antigen-specific T cell response 
and the viral replication occur. APCs, primarily DCs, function by obtaining antigens in 
the periphery, migrating to draining lymph nodes (LNs), and interacting with antigen-
specific T cells, leading to the T cell activation and antigen-specific responses. However, 
in the context of HIV infection, the interaction between viral antigen-expressing APC and 
HIV-specific T cells could blunt the immune response through multiple mechanisms 65, 
168. It has been suggested that DC-T cell interaction can stimulate viral replication in DC, 
CD4+ T cells and the cell conjugates, which represent an explosive site of HIV infection 
that could escape from ART 128. Multiple mechanisms have been proposed for this 
suppressed T cell activation induced by the inappropriate deleterious DC-T interactions 
in LN during HIV infection, including T cell death secondary to activation of latent 
infection, aberrant signals from DCs expressing inhibitory HIV proteins, and CD4+ T cell 
fusion with infected DCs or DCs expressing Env. Collectively, the mechanisms for the 
impaired antigen-specific T cell response in chronic HIV are complex and not fully 
understood.   
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Aims of thesis 
          In this thesis, I have examined the mechanisms for the inhibition of CD4+ T cell 
immunity in HIV. An in vitro system modeling the interaction between HIV Env and 
human primary CD4+ T cells will be used to study the inhibitory effect of Env protein, 
when delivered as a vaccine on APC and non-APC, or as free virions, on antigen-
stimulated bystander CD4+ T cell proliferation. I investigate the mechanisms by studying 
various forms of T cell inhibition, including anergy, apoptosis and cell death. Some 
important TCR and cytokine signaling pathways are also investigated in CD4+ cells with 
Env exposure. Considering the suppressive effect of human Treg cells on autologous 
CD4+ and CD8+ T cell proliferation and its ability to interact with HIV Env, I study the 
regulation of Treg frequency, activation phenotype, and suppressive activity in human 
peripheral blood by Env, and the functional involvment of Treg cells in Env-induced 
inhibition.  
 
          In the third chapter of this thesis, I move the studies to an in vivo model. Using 
chronically SIV and CMV co-infected, ART-treated rhesus macaques, I study the early 
immunologic and virologic consequences of immunization with SIV and CMV antigen in 
draining lymph nodes, where antigen presentation, antigen-specific T cell responses and 
viral replication occur during infection. The systemic response in peripheral blood after 
immunization is also studied to track the fate of immunization-induced antigen-specific T 
cells. 	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CHAPTER 2 
HIV Envelope Suppresses CD4+ T Cell Activation Independent of 
T Regulatory Cells 
Introduction 
          One of the hallmarks of HIV-associated defects in cell-mediated immunity is the 
progressive loss of CD4+ T cell responses, even before a significant decrease in 
peripheral blood CD4+ T cell numbers occurs 105. The Env protein of the virus is a key 
component of an effective vaccine because it exclusively induces neutralizing antibodies, 
which are protective in the macaque model 100. However, Env has been demonstrated to 
suppress CD4+ T cells by multiple mechanisms. Inhibition has been characterized by a 
lack of proliferation82, 132, the induction of anergy 93, 99, and various apoptotic 
mechanisms10, 165. The role of Env interactions with CD4 and coreceptors in mediating 
the various forms of suppression is under debate with studies demonstrating a role for 
each 7, 15, 154. R5 Env caused apoptosis of CD4+ T cells from a CCR5∆32 homozygous 
donor, whereas, in another study, Env interaction with CXCR4 and a nonsignaling CD4 
induced CD4+ T cell apoptosis130. The mechanism of suppression observed and the 
receptors involved varied according to the nature of Env used and the cell culture system 
studied. Env is a trimeric protein with each of its monomers possessing a CD4 binding 
site. Thus, an Env trimer 132 or aggregates created by antibodies against monomeric 
gp120 subunits 10 can mediate cross-linking of CD4 and/or coreceptor leading to 
signaling. In patients infected with HIV, trimeric Env capable of suppression is found on 
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the surface of infected cells as well as on the virus itself. The use of Env in HIV vaccines, 
especially in commonly used DNA and viral vectors, could be envisioned to deliver 
similar CD4+ T cell suppressive signals.  
           
           Although APCs such as DCs are prime targets for vaccines, other cell types at the 
site of vaccine delivery, and potentially the major vaccine antigen expressing cell types, 
are non-APCs such as myocytes, fibroblasts, subepithelial, and epithelial cells for muscle, 
dermal, subcutaneous, and mucosal delivery, respectively, as well as cells in the draining 
lymph nodes 30, 38. CD4+ T cells that are recruited to the site of vaccine delivery as well as 
to the draining lymph node in response to vaccine-induced inflammation may then 
interact with and be suppressed by interaction with Env expressed on the surface of all of 
these cells.  
 
            Naturally occurring regulatory T cells (Treg) are a subset of CD4+ T cells co-
expressing CD25 and FoxP3 and have the ability to suppress autologous CD4+ and CD8+ 
T cell activation and proliferation. The role of Treg cells in HIV has been intensively 
studied and there are accumulating evidence supporting the active engagement of Treg 
cells in modulating immune response towards HIV infection 1, 86, 112, 161. Issues with 
regard to whether and how HIV regulates the frequency and function of Treg cells during 
infection, and how this regulation relates to HIV pathogenesis and host immunity, 
remains highly controversial. There is limited evidence, so far, demonstrating the direct 
interaction of Treg cells and HIV or its gene products. One study showed that HIV 
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interacts directly with Treg cells through Env-CD4 signaling and increases Treg 
frequency in PBMC through selectively enhancing Treg viability and the subsequent 
accumulation of Treg cells 112.    
 
            In this chapter, using an in vitro system that models the in vivo interaction 
between CD4+ T cells and Env, we investigated the mechanisms for how Env suppresses 
CD4+ T cells concentrating on signaling pathways and the involvement of Tregs.  
 
Materials and Methods 
Cells and HIV-1 
Human embryonic kidney 293T cells (American Type Culture Collection) were 
maintained in DMEM (Invitrogen Life Technologies) supplemented with 10% FCS 
(HyClone) and glutamine (Invitrogen Life Technologies). Monocyte-derived dendritic 
cells were obtained from purified monocytes (Center for AIDS Research (CFAR) 
Immunology core) and plated in 6-well plates at 3 x 106 cells in 3 mls of AIM V serum-
free media (Life Technologies, Rockville, MD), supplemented with GM-CSF (50 ng/ml) 
and IL-4 (100 ng/ml). After 3 days, cells were fed by adding 1.5 mls of Aim V 
supplemented with GM-CSF and IL-4. Peripherable blood mononuclear cells (PBMC) 
from HIV-negative donors were obtained through an IRB-approved protocol and 
maintained in complete RPMI 1640 (Invitrogen Life Technologies) containing 10% FCS 
and glutamine. Aldrothiol-2 (AT-2) inactivated 131 HIV-1 NL4–3 virions were obtained 
from University of Pennsylvania CFAR virology core. 
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Plasmid constructs and RNA synthesis 
HIV Envs IIIB, YU2, and 89.6 were cloned into the RNA expression plasmid 
pT7TS that contains a T7 promoter, 5’ and 3’ UTR sequences of Xenopus-globin, and a 
30-nuc long poly (A) tail 80. Plasmids were linearized with restriction enzymes and in 
vitro transcribed with T7 polymerase (mMessage T7 Ultra Kits (Ambion)), extended 
poly-A tail wer added. RNA was maintained in nuclease-free water at a concentration of 
1 µg/µl and stored at -20°C. 
 
DC infection with vaccinia virus 
             DCs were suspended at a concentration of 2 million/mL and infected with 
vaccinia-encoding IIIB, MN, or 92UG037.8 Env (NIH AIDS Research and Reference 
Reagent Program), T7 Polymerase (VTF7.3), or wild-type WR strain for 2 hours, 
washed, and incubated for 4 hours. Infected DCs were cocultured with 5-and 6-
carboxyfluorescein diacetate, succinimidyl ester (CFSE)-labeled PBMCs at a ratio of 
1:10 and activated with 0.1 µg/mL toxic shock syndrome toxin-1 (TSST-1) superantigen. 
 
 
Exposure of CD4+ T cells to Env and CD4+ T cell proliferation 
Transcribed mRNA encoding HIV Env was complexed to lipofectin for delivery 
to cells as described previously 80. 293T cells seeded in 12-well plates, approximately 
90% confluent (5 x 105 cells), were transfected with Env (IIIB, YU2, and 89.6) encoding 
mRNA (5 µg/ml) or control poly(AC) RNA (Sigma-Aldrich), incubated for 4 h to allow 
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protein expression, and cocultured with 2 x 106 CFSE loaded PBMC in the presence of 
stimulation with soluble anti-CD3 mAb (1 µg/ml; Ortho Biotech) or 0.1 µg/mL 
superantigen TSST-1 (Sigma) and IL-2 (20 U/ml; AIDS Reference and Reagent Program) 
with or without soluble CD4 (sCD4) (10 µg/ml; AIDS Reference and Reagent Program). 
Increasing or decreasing the ratio of Env-expressing 293T cells to PBMC did not affect 
suppression of CD4+ T cell proliferation. For exposure to free virions, 2 x 106 CFSE-
labeled PBMC were incubated with AT-2-inactivated HIV-1 NL4-3 virions at 
concentrations of 1, 0.3, or 0.1 µg HIV p24 Gag equivalents/ml, which corresponds to a 
gp120 concentration of 1, 0.3, and 0.1 nM, respectively 112. Four days after Env exposure, 
PBMC were collected, washed with PBS containing 1% FCS, and stained with anti-CD4-
allophycocyanin (RPA-T4; BD Pharmingen). Cells were analyzed on a FACS-Calibur 
flow cytometer, and proliferation of CD4+ T cells was analyzed by CFSE dilution using 
Cellquest software (BD Pharmingen). A minimum of 10,000 events were analyzed. The 
percent of stimulated CD4+ T cells that proliferated was calculated as described 164.  
 
Detection of apoptosis and activation in CD4+ T cells exposed to Env  
PBMCs were cocultured with Env-expressing 293T cells or 700 µM 
cycloheximide (Sigma) and activated with 0.1 µg/mL TSST-1 or 1 µg/mL anti-CD3 
mAb. Apoptosis was examined 6, 17, and 36 hours after coculture and identified as 
annexin V-positive (BD Pharmingen, San Diego, CA) and 7-AAD–negative (Sigma) 
cells. Total cell death was measured by positive staining for 7-AAD in ungated cells. For 
studies measuring up-regulation of activation markers in Env-treated PBMCs, CD69 
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peridinin chlorophyll protein (day 1), HLA-DR fluorescein isothiocyanate and CD25 
phycoerythrin cyanine 7 (BD Immunocytometry Systems, San Jose, CA) (day 2) were 
used. 
 
Deetection of phosphorylation of signaling molecules in CD4+ T cells  
Purified CD4+ T cells were exposed to IIIB Env-expressing 293T cells for 1 day, 
stimulated with 1 µg/mL anti-CD3 antibody for 10 minutes for p38 or 2 days followed by 
20 U/mL IL-2 for 2 to 20 minutes for STAT5a, fixed, and analyzed by flow cytometry 
using anti–phospho-MAPK (pT180/ pY182) Alexa Fluor 647 or anti-phospho-STAT5 
(pY694) Alexa Fluor 647 (BD Pharmingen), respectively. For AKT phosphorylation, 
PBMCs were cocultured with IIIB Env-expressing 293T cells for 2 hours in complete 
DMEM and then for 18 hours in DMEM with 0.5% serum, stimulated with 1 µg/mL anti-
CD3 antibody for 10 minutes, fixed, and stained with anti–phospho-AKT (ser 473) Alexa 
Fluor 488 (Cell Signaling Technologies, Danvers, MA) and anti-CD4 v4 (clone L120) 
phycoerythrin (BD Immunocytometry Systems). 
 
CD25+ cell depletion and T cell proliferation assay 
CD25+ cells were depleted from PBMC using magnetic beads (Dynabeads CD25; 
Invitrogen Life Technologies). Briefly, PBMC and magnetic beads were washed twice 
with PBS containing 1% FBS. Then 1 x 107 cells/ml were mixed with a 40:1 ratio of 
beads to CD25+ cells assuming 5% of cells expressed CD25, and rotated at 4°C for 45 
minutes. A second round of depletion was performed with a decreased volume of beads 
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(half of that used in the first round) to achieve near complete depletion of CD25+ cells. 
Whole and CD25-depleted PBMC were CFSE labeled, and cultured with Env-expressing 
and control 293T cells in presence of TCR stimulation. 
 
Treg sorting and suppression culture 
 Whole PBMC or CD25-depleted PBMCs were cultured with Env-expressing or 
control 293T cells. During Env exposure, whole PBMC were unstimulated, whereas 
CD25-depleted PBMC were stimulated with anti-CD3 and IL-2 to expand induced Tregs. 
A total of 48 h after Env exposure, PBMC were removed from 293T monolayers and 
stained with anti-CD4-FITC, anti-CD25-PE-Cy5, and anti-CD127-PE (BD PharMingen). 
CD4+, CD127-, CD25+ cell sorting was performed on a FACS/Aria (BDbioscience) to 
obtain Tregs. A total of 2 x 105 CFSE labeled CD25-depleted autologous PBMC 
responders were mixed with increasing amounts of FACS sorted CD4+, CD127-, CD25+ 
Tregs (Suppressor to Responder ratios of 1:3 and 1:6) in the presence of stimulation with 
anti-CD3 and IL-2. Four days after coculture, the proliferation of responder cells was 
determined by flow cytometry. 
 
Treg analyses 
 PBMC were exposed to Env (either on 293T as AT-2-treated virions) as described 
above. For exposure to 293T cells, PBMC were either resting or stimulated by anti-CD3 
and IL-2. For incubation with AT-2 inactivated virions, resting PBMCs were used. At 
various time points after Env exposure (days 1, 3, and 5), PBMC were collected, washed 
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with PBS containing 1% FCS, and stained with anti-human CD4-FITC (SK3; BD 
Pharmingen) and anti-CD25-PE-Cy5 (M-A251; BD Pharmingen). Cells were then 
washed, fixed with 2% paraformaldehyde (eBiosicence), permeabilized with PBS 1% 
FCS containing 0.1% saponin (eBioscience), incubated with normal rat serum at 4°C for 
15 min, and stained with anti-human FoxP3-allophycocyanin (PCH101; eBioscience) on 
ice for 30 min according to the manufacturer’s instructions. The appropriate isotype-
matched Abs were used to define background staining. Expression of CD4, CD25, and 
FoxP3 in cells were determined by flow cytometry. A minimum of 10,000 events were 
analyzed. 
 
IL-10 and TGF-β ELISA 
  IL-10 and TGF-β concentrations in culture supernatants were determined by 
commercially available ELISA kits (BD OptEIA) according to the manufacturer’s 
instructions.  
 
Statistics 
  Mean, standard error of the mean (SEM), and student’s t-test were performed using 
Microsoft Excel software.  
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Results 
Env expressed on 293T cells induces suppression of CD4+ T cell proliferation  
             Following vaccine delivery, a number of cell types other than APCs take up and 
express vaccine-derived antigens. Expression by these cells presents Env in the absence 
of costimulatory molecules. 293T cells were transfected with Env-encoding mRNA as 
consistent, and low-level protein expression is obtained in most cells 163, allowing 
uniform exposure of CD4+ T cells to Env. PBMCs were used as a source of CD4+ T cells 
and cocultured with 293T cells expressing X4-tropic IIIB, dual tropic 89.6, and M-tropic 
JR-Fl, YU-2, and SF162 Envs. Cells were stimulated with a concentration of anti-CD3 
mAb that typically stimulates one quarter of the CD4+ T cells. To monitor proliferation, 
PBMCs were stained with CFSE??. CD4+ T cells that encountered any of the Envs had 
lower proliferation levels compared with cultures exposed to control RNA-transfected 
293T cells (Figure 2.1A). Similar inhibition was observed when cells were activated by 
the superantigen TSST-1, a model antigen for activation via the T-cell receptor (TCR), 
which requires the same costimulatory and adhesion molecules as conventional antigens 
138. This suggested that suppression of proliferation was not dependent on a particular 
mode of activation. In addition, negatively selected purified CD4+ T cells exposed to Env 
also failed to proliferate, arguing against a role for CD8+ T cells and natural killer cells in 
mediating suppression (Figure 2.1B). 
 
           To characterize the signal delivered by Env, we examined whether suppression 
could be overcome by blocking Env interaction with CD4. sCD4 almost completely 
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abrogated Env-induced suppression (Figure 2.1A). P-values were calculated using results 
from 3 independent experiments. A paired Student t-test with 2 tails was performed using 
the percentage of change from control across experiments (no Env) or sCD4 treatment 
and is shown in Table 1.  
 
             Expression of functional trimeric Env on 293T cells was confirmed in fusion 
assays demonstrating that mRNA delivery resulted in surface expression of fusion-
competent Env (Figure 2.1C-D). Delivery of Env-containing vaccines in vivo results in a 
variety of expression levels that are governed by the cellular vaccine target and the 
vaccine delivery method. In our experimental system that mimics vaccination with Env, 
we chose delivery of Env by encoding mRNA to 293T cells, which results in expression 
of Env in nearly 100% of cells at lower levels compared with other methods of delivery, 
such as DNA. This was important as lymphocyte trafficking does not occur in our 
system. Thus, if only 25% of the cells expressed Env, then only about 25% of the CD4+ T 
cells added would be exposed. This low level of expression was sufficient to mediate 
suppression, and, in fact, a 5-fold reduction in the quantity of Env encoding mRNA 
delivered, which results in a 5-fold lower level of protein expressed, resulted in similar 
levels of suppression (data not shown). Thus, at the range of expression levels seen in our 
culture system, large variations in the amount of Env expressed did not alter the degree of 
suppression exerted. This could explain the lack of correlation observed between the 
degree of suppression mediated by an Env strain (Figure 2.1A) and the amount of fusion 
mediated (Figure 2.1C-D).  
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            Several reports have found that trimeric or aggregated forms of Env are required 
to mediate suppression 10, 93. However, others have found that monomeric gp120 could 
exert suppressive effects 82 165. In our system, CD4+ T cells were exposed to trimeric cell-
surface expressed Env as well as monomeric gp120 released into the supernatant, likely 
from dissociation of cell-surface gp160. PBMCs exposed exclusively to exogenous 
monomeric gp120 derived from IIIB or SF162 failed to suppress CD4+ T cell 
proliferation (Table 2). The added gp120 retained the ability to block binding of CD4 
mAb (leu-3a) demonstrating functional binding to CD4. This confirmed that trimeric 
surface expressed Env-mediated suppression in our system. Thus, transfection of 293T 
cells with encoding mRNA resulted in surface expression of functional Env, which 
mediated inhibition of antigen-specific CD4+ T cell proliferation in a CD4-dependent 
manner.  
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Figure 2.1 
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Figure 2.1. HIV Env suppresses anti-CD3-activated CD4+ T cell proliferation. (A) 
293T cells expressing IIIB, 89.6, YU-2, SF162, and JR-Fl Envs or no Env poly (A,C) 
RNA transfected) were cocultured with CFSE-labeled PBMCs with or without sCD4 (10 
µg/ml). T cells were activated with anti-CD3 mAb (0.5 µg/mL), and monitored for 
proliferation 4 days after coculture by flow cytometry with staining with anti-CD4 mAb. 
(B) Negatively selected purified CD4+ T cells were cocultured with 293T cells 
expressing IIIB Env or no Env and activated using anti-CD3 mAb (0.5 µg/mL). 
Quadrants are labeled with the percent of events in each. Fusion assays demonstrated 
surface expression of functional Env. Encoding mRNA-transfected 293T cells were 
mixed with QT6 cells expressing CD4 and CXCR4 (C) or CCR5 (D), and fusion of the 2 
cell populations was measured by luciferase production. Experiments shown are 
representative of 3 independent experiments. 
	  
	   30	   	   	  
	  
 
DCs expressing Env suppress CD4+ T cell proliferation 
	  
           Presentation of vaccine-derived antigens by APCs activates immune responses and 
is the basis of an effective vaccine. APCs, such as DCs in their mature form, express a 
variety of costimulatory molecules on their surface and provide a strong activation signal 
for T and B cells. Certain studies have shown that activation, including potent 
costimulation, could overcome suppression induced by CD4 cross-linking 146. Other 
studies have not supported this, demonstrating that HIV-infected DCs were able to 
suppress CD4+ T cells in an Env-dependent fashion. Currently, viral vector or nucleic 
costimulatory and adhesion molecules as conventional anti-
gens.28,29 This suggested that suppression of proliferation was not
dependent on a particular mode of activation. In addition, nega-
tively selected purified CD4! T cells exposed to Env also failed to
proliferate, arguing against a role for CD8! T cells and natural
killer cells in mediating suppression (Figure 1B).
To characterize the signal delivered by Env, we examined
whether suppression could be overcome by blocking Env interac-
tion with CD4. Soluble (s)CD4 almost completely abrogated
Env-induced suppression (Figure 1A). P values were calculated
using results from 3 independent experiments. A paired Student t
test with 2 tails was performed using the percentage of change from
control across experiments (no Env) or sCD4 treatment and is
shown in Table 1.
Expression of functional trimeric Env on 293T cells was
confirmed in fusion assays demonstrating that mRNA delivery
resulted in surface expression of fusion-competent Env (Figure
1C-D). Delivery of Env-containing vaccines in vivo results in a
variety of expression levels that are governed by the cellular
vaccine target and the vaccine delivery method. In our experimen-
tal system that mimics vaccination with Env, we chose delivery of
Env by encoding mRNA to 293T cells, which results in expression
of Env in nearly 100% of cells at much lower levels compared with
other methods of delivery, such as DNA. This was important as
lymphocyte trafficking does not occur in our system. Thus, if only
25% of the cells expressed Env, then only about 25% of the CD4!
T cells added would be exposed. This low level of expression was
sufficient to mediate suppression, and, in fact, a 5-fold reduction in
the quantity of Env encoding mRNA delivered which results in a
5-fold lower level of protein expressed resulted in similar levels of
suppression (data not shown). Thus, at the range of expression
levels seen in our culture system significantly large variations in the
amount of Env expressed did not alter the degree of suppression
exerted. This could explain the lack of correlation observed
between the degree of suppression mediated by an Env strain
(Figure 1A) and the amount of fusion mediated (Figure 1C-D).
Several reports have found that trimeric or aggregated forms of
Env are required to mediate suppression.5,8 However, others have
found that monomeric gp120 could exert suppressive effects.3,7 In
our system, CD4! T cells were exposed to trimeric cell-surface–
expressed Env as well as monomeric gp120 released into the
supernatant, likely from dissociation of cell-surface gp160. PBMCs
exposed exclusively to exogenous monomeric gp120 derived from
IIIB or SF162 failed to suppress CD4! T-cell proliferation (Table
2). The added gp120 retained the ability to block binding of CD4
mAb (leu-3a) demonstrating functional binding to CD4. This
confirmed that trimeric surface expressed Env-mediated suppres-
sion in our system. Thus, transfection of 293T cells with encoding
mRNA resulted in surface expression of functional Env, which
mediated inhibition of antigen-specific CD4! T-cell proliferation in
a CD4-dependent manner.
DCs expressing Env suppress CD4! T-cell proliferation
Presentation of vaccine-derived antigens by APCs activates im-
mune responses and is the basis of an effective vaccine. APCs, such
as DCs in their mature form, express a variety of costimulatory
molecules on their surface and provide a strong activation signal
for T and B cells.30 Certain studies have shown that activation,
including potent costimulation, could overcome suppression in-
duced by CD4 cross-linking.31 Other studies have not supported
this, demonstrating that HIV-infected DCs were able to suppress
CD4! T cells in an Env-dependent fashion.3 Currently, viral vector
or nucleic acid delivery of encoding antigen to DCs (either directly
in vivo or after in vitro culture and loading of DCs) is in human
trials and represents a potent vaccine approach.32,33 We infected
DCs with vaccinia virus encoding various Envs34,35 and tested their
ability to affect CD4! T-cell proliferation in response to superanti-
gen. DCs expressing the X4 Envs IIIB and MN and the R5 Env
92UG037.8 (a Clade A primary isolate) were found to inhibit CD4!
T-cell proliferation to antigen, which was overcome by sCD4
(Figure 2; data not shown). The P values comparing IIIB Env to no
Env or sCD4 treatment were less than .005. Expression of Env by
these types of vectors in vitro has been previously demon-
strated.34-36 Very low multiplicities of infection (MOIs) of vaccinia
were used as T-cell toxicity was observed at MOIs typically used in
fusion assays. However, even at low MOIs (0.3-0.6) a minority of
the suppression could not be overcome with sCD4. This Env-
independent suppression of T-cell proliferation was also observed
with 2 control viruses, vTF7-323 encoding T7 Polymerase and WR,
the strain used to create all of the Env-expressing and control
viruses. We concluded that vaccinia viruses had a small but
significant level of toxicity in our system, which accounts for the
inability of sCD4 to completely overcome the suppression of
Table 1. Statistical analysis of suppression of CD4! T cells
proliferation by Env
Env strain
P of suppression compared
with no Env control
P of suppression compared
with sCD4 treatment
IIIB " .005 " .005
89.6 .01 .02
JR-F1 .02 .04
Yu-2 .01 .02
P values were calculated using results from 3 independent experiments.
Percentage of change from control (no Env) or sCD4 treatment was used in a paired
Student t test with 2 tails.
Table 2. Effect of monomeric gp120 on CD4! T-cell proliferation
No Env IIIB gp120 SF162 gp120
CD4! cells undergoing
proliferation, % 15.3 14.4 12.5
CD4# cells undergoing
proliferation, % 7.7 7.4 7.3
Anti-CD3 mAb (0.5 $g/mL) stimulated CFSE-labeled PBMCs were exposed to 2
$g/mL IIIB or SF162 gp120 or left untreated. CD4! T cells were monitored for
proliferation 4 days after coculture by flow cytometry and expressed as percentage of
total CD4! T cells.
Figure 2. DCs expressing Env and presenting antigen suppress CD4! T-cell
proliferation. DCs were infected with vaccinia virus encoding IIIB Env or control
vaccinia encoding T7 polymerase and cocultured with CFSE-labeled PBMCs with 0.1
ng/mL TSST-1 and with or without sCD4. This concentration of superantigen requires
presentation by DCs as no proliferation is observed in their absence. Proliferation of
CD4! T cells was measured 5 days later by flow cytometry. Quadrants are labeled
with the percent of events in each. Experiments shown are representative of 3
independent experiments.
2540 FERNANDO et al BLOOD, 15 MARCH 2007 ! VOLUME 109, NUMBER 6
 For personal use only. at University of Pennsylvania Library on January 4, 2010. www.bloodjournal.orgFrom 
costimulatory and adhesion molecules as conventional anti-
gens.28,29 This suggested that suppression of proliferation was not
dependent on a particular mode of activation. In addition, nega-
tively selected purified CD4! T cells exposed to Env also failed to
proliferate, arguing against a role for CD8! T cells and natural
killer cells in mediating suppression (Figure 1B).
To characterize the signal delivered by Env, we examined
whether suppression could be overcome by blocking Env interac-
tion with CD4. Soluble (s)CD4 almost completely abrogated
Env-induced suppression (Figure 1A). P values were calculated
using results from 3 independent experiments. A paired Student t
test with 2 tails was performed usi g the percentage of change from
control across experiments (no Env) or sCD4 treatment and is
shown in Table 1.
Expression of functional trimeric Env on 293T cells was
confirmed in fusion assays demonstrating that mRNA delivery
resulted in surface expression of fusion-competent Env (Figure
1C-D). Delivery of Env-containing vaccines in vivo results in a
variety of expression levels that are governed by the cellular
vaccine target and the vaccine delivery method. In our experimen-
tal system that mimics vaccination with Env, we chose delivery of
Env by encoding mRNA to 293T cells, which results in expression
of Env in nearly 100% of cells at much lower levels compared with
other methods of delivery, such as DNA. This was important as
lymphocyte trafficking does not occur in our system. Thus, if only
25% of the cells expressed Env, then only about 25% of the CD4!
T cells added would be exposed. This low level of expression was
sufficient to mediate suppression, and, in fact, a 5-fold reduction in
the quantity of Env encoding mRNA delivered which results in a
5-fold lower level of protein expressed resulted in similar levels of
suppression (data not shown). Thus, at the range of expression
levels seen in our culture system significantly large variations in the
amount of Env expressed did not alter the degree of suppression
exerted. This could explain the lack of correlation observed
between the degree of suppression mediated by an Env strain
(Figure 1A) and the amount of fusion mediated (Figure 1C-D).
Several reports have found that trimeric or aggregated forms of
Env are required to mediate suppression.5,8 However, others have
found that monomeric gp120 could exert suppressive effects.3,7 In
our system, CD4! T cells were exposed to trimeric cell-surface–
expressed Env as well as monomeric gp120 released into the
supernatant, likely from dissociation of cell-surface gp160. PBMCs
exposed exclusively to exogenous monomeric gp120 derived from
IIIB or SF162 failed to suppress CD4! T-cell proliferation (Table
2). The added gp120 retained the ability to block binding of CD4
mAb (leu-3a) demonstrating functional binding to CD4. This
confirmed that trimeric surface expressed Env-mediated suppres-
sion in our system. Thus, transfection of 293T cells with encoding
mRNA resulted in surface expression of functional Env, which
mediated inhibition of antigen-specific CD4! T-cell proliferation in
a CD4-dependent manner.
DCs expressing Env suppress CD4! T-cell proliferation
Presentation of vaccine-derived antigens by APCs activates im-
mune responses and is the basis of an effective vaccine. APCs, such
as DCs in their mature form, express a variety of costimulatory
molecules on their surface and provide a strong activation signal
for T and B cells.30 Certain studies have shown that activation,
including potent costimulation, could overcome suppression in-
duced by CD4 cross-linking.31 Other studies have not supported
this, demonstrating that HIV-infected DCs were able to suppress
CD4! T cells in an Env-dependent fashion.3 Currently, viral vector
or nucleic acid delivery of encoding antigen to DCs (either directly
in vivo or after in vitro culture and loading of DCs) is in human
trials and represents a potent vaccine approach.32,33 We infected
DCs with vaccinia virus encoding various Envs34,35 and tested their
ability to affect CD4! T-cell proliferation in response to superanti-
gen. DCs expressing the X4 Envs IIIB and MN and the R5 Env
92UG037.8 (a Clade A primary isolate) were found to inhibit CD4!
T-cell proliferation to antigen, which was overcome by sCD4
(Figure 2; data not shown). The P values comparing IIIB Env to no
Env or sCD4 treatment were less than .005. Expression of Env by
these types of vectors in vitro has been previously demon-
strated.34-36 Very low multiplicities of infection (MOIs) of vaccinia
were used as T-cell toxicity was observed at MOIs typically used in
fusion assays. However, even at low MOIs (0.3-0.6) a minority of
the suppression could not be overcome with sCD4. This Env-
independent suppression of T-cell proliferation was also observed
with 2 control viruses, vTF7-323 encoding T7 Polymerase and WR,
the strain used to create all of the Env-expressing and control
viruses. We concluded that vaccinia viruses had a small but
significant level of toxicity in our system, which accounts for the
inability of sCD4 to completely overcome the suppression of
Table 1. Statistical analysis of suppression of CD4! T cells
proliferation by Env
Env strain
P of suppression compared
with no Env control
P of suppression compared
with sCD4 treatment
IIIB " .005 " .005
89.6 .01 .02
JR-F1 .02 .04
Yu-2 .01 .02
P values were calculated using results from 3 independent experiments.
Percentage of change from control (no Env) or sCD4 treatment was used in a paired
Student t test with 2 tails.
Table 2. Effect of monomeric gp120 on CD4! T-cell proliferation
No Env IIIB gp120 SF162 gp120
CD4! cells undergoing
proliferation, % 15.3 14.4 12.5
CD4# cells undergoing
proliferation, % 7.7 7.4 7.3
Anti-CD3 mAb (0.5 $g/mL) stimulated CFSE-labeled PBMCs were exposed to 2
$g/mL IIIB or SF162 gp120 or left untreated. CD4! T cells were monitored for
proliferation 4 days after coculture by flow cytometry and expressed as percentage of
total CD4! T cells.
Figure 2. DCs expressing Env and presenting antigen suppress CD4! T-cell
proliferation. DCs were infected with vaccinia virus encoding IIIB Env or control
vaccinia encoding T7 polymerase and cocultured with CFSE-labeled PBMCs with 0.1
ng/mL TSST-1 and with or without sCD4. This concentration of superantigen requires
presentation by DCs as no proliferation is observed in their absence. Proliferation of
CD4! T cells was measured 5 days later by flow cytometry. Quadrants are labeled
with the percent of events in each. Experiments shown are representative of 3
independent experiments.
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acid delivery of encoding antigen to DCs (either directly in vivo or after in vitro culture 
and loading of DCs) is in human trials and represents a potent vaccine approach 62, 111. 
We infected DCs with vaccinia virus encoding various Envs and tested their ability to 
affect CD4+ T cell proliferation in response to superantigen. DCs expressing the X4 Envs 
IIIB and MN and the R5 Env 92UG037.8 (a Clade A primary isolate) were found to 
inhibit CD4+ T cell proliferation to antigen, which was overcome by sCD4 (Figure 2.2). 
The p-values comparing IIIB Env to no Env or sCD4 treatment were less than 0.005. 
Expression of Env by these types of vectors in vitro has been previously demonstrated59, 
76, 121. Very low multiplicities of infection (MOIs) of vaccinia were used as T-cell toxicity 
was observed at MOIs typically used in fusion assays. However, even at low MOIs (0.3-
0.6) a minority of the suppression could not be overcome with sCD4. This suppression of 
T-cell proliferation was also observed with 2 control viruses, vTF7-3 encoding T7 
Polymerase and WR, the strain used to create all of the Env-expressing and control 
viruses, suggesting a vaccinia mediated suppression was also present. We concluded that 
vaccinia viruses had a small but significant level of toxicity in our system, which 
accounts for the inability of sCD4 to completely overcome the suppression of 
proliferation. In addition, the ability of Env to interact with CD4 molecules on DCs and 
suppress their maturation and function cannot be ruled out in our system, as it has been 
observed in other systems 54, 167. Expression of functional Env was confirmed in fusion 
assays between DCs and Quail cells (data not shown). Thus, mature DCs expressing Env 
mediate suppression of antigen-specific CD4+ T cell proliferation despite expressing 
multiple costimulatory molecules. 
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Figure 2.2 
 
Figure 2.2. DCs expressing Env and presenting antigen suppress CD4+ T cell 
proliferation. DCs were infected with vaccinia virus encoding IIIB Env or control 
vaccinia encoding T7 polymerase and cocultured with CFSE-labeled PBMCs with 0.1 
µg/mL TSST-1 with or without sCD4 (10 µg/ml). This concentration of superantigen 
requires presentation by DCs as no proliferation is observed in their absence. 
Proliferation of CD4+ T cells was measured 5 days later by flow cytometry. Quadrants 
are labeled with the percent of events in each. Experiments shown are representative of 3 
independent experiments. 
 
Neither apoptosis nor IL-2-dependent anergy mediate CD4+ T cell suppression                        
            Env-induced CD4+ T cell dysfunction has been described as anergy, apoptosis, 
cell death, or a failure to proliferate. We observed that Env suppresses CD4+ T cells in 
our system by hindering proliferation. We next investigated whether anergy or apoptosis 
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occurred. PBMCs were cocultured with Env-expressing 293T cells and were activated 
using TSST-1 superantigen. 6, 18, and 36 hours later, CD4+ T cells were analyzed for 
early apoptosis using annexin V staining of 7-AAD–negative cells. Cyclohexamide is a 
protein synthesis inhibitor that induces apoptosis of PBMCs and was used as a positive 
control. Env failed to induce apoptosis of CD4+ T cells above the level seen in cells 
unexposed to Env (Figure 2.3A). In addition, an increase in cell death (7-AAD uptake in 
ungated cells) in Env-exposed CD4+ T cells was not observed (Figure 2.3B). Thus, 
apoptosis and cell death are not major contributors to the suppression of proliferation 
induced by Env in our system. T-cell anergy is defined as a state of nonresponsiveness to 
activation with antigen. The addition of exogenous IL-2 overcomes most but not all types 
of anergy 133. Selliah and Finkel observed that CD4+ T cell suppression induced by Env 
could be overcome with exogenous IL-2 134. To investigate this mechanism, CFSE-
stained PBMCs were cultured with control or Env-expressing 293T cells and activated 
with TSST-1 in the presence of increasing amounts of exogenous IL-2 (20, 40, or 80 
U/mL). IL-2 was unable to prevent suppression of proliferation of CD4+ T cells by Env 
(Figure 2.3C, and data not shown), arguing against this form of anergy as the mechanism 
of suppression.  
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Figure 2.3 
 
Figure 2.3. Neither apoptosis nor IL-2-dependent anergy mediate Env-induced 
CD4+ T cell suppression. PBMCs were cocultured with IIIB Env or luciferase-
expressing 293T cells or 700 µM cycloheximide (CHX) and activated with 0.1 µg/mL 
TSST-1. Thirty-six hours later, apoptotic CD4+ T cells were analyzed by flow cytometry 
and defined as Annexin V positive and 7-AAD negative, early apoptotic cells (A) and 7-
AAD positive for dead cells (B). (C) CFSE-labeled PBMCs were cocultured with IIIB 
Env-expressing 293T cells in the presence of 80 U/mL IL-2 and activated with 0.1 µg/mL 
TSST-1. CD4+ T cell proliferation was measured 5 days later by flow cytometry. 
Quadrants labeled with percent of events in each. Experiments shown are representative 
of 3 independent experiments. 
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CD4+ T cells activated in the presence of Env phosphorylate AKT, MAPK, and 
STAT5a but fail to completely up-regulate activation markers 
           CD4+ T cells exposed to Env failed to proliferate in response to antigen but did not 
apoptose, anergize, or die. We next sought to determine the location of the block in the 
activation cascade. In response to T cell activation, phosphorylation of key signaling 
molecules p38 MAPK and AKT relay the TCR signal to downstream mediators 44, 133 
CD4+ T cells exposed to Env and activated by anti-CD3 phosphorylated AKT and MAPK 
similar to control treated cells (Figure 2.4).  IL-2 is an important cytokine involved in T-
cell proliferation, and its binding to both the low and high affinity IL-2R leads to the 
phosphorylation of STAT5a 78. Exogenous IL-2 was unable to circumvent the 
suppression of proliferation induced by Env (Figure 2.3C), but cells exposed to and 
suppressed by Env were able to phosphorylate STAT5a in response to IL-2 (Figure 
2.4B), suggesting that early signaling mediators in the IL-2 cascade also were not 
impaired. On activation, CD4+ T cells go through a series of events prior to proliferation, 
including up-regulation of markers of activation such as CD69, HLA-DR, and CD25 39. 
PBMCs were exposed to IIIB Env-expressing 293T cells and activated using anti-CD3 or 
superantigen. Up-regulation of CD69 (day 1) and HLA-DR and CD25 (day 2) was 
monitored using flow cytometry. CD4+ T cells exposed to Env were unable to completely 
up-regulate their activation markers (Table 3). Thus, although exposure of CD4+ T cells 
to Env did not suppress the phosphorylation of immediate signaling mediators, it 
suppressed the upregulation of early and late cell-surface markers of activation. 
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Figure 2.4 
 
Figure 2.4. CD4+ T cells activated in the presence of Env phosphorylate AKT, p38 
MAPK, and STAT5a. PBMCs were cocultured with Env or control RNA-expressing 
293T cells for 24 hours. Phosphorylation of AKT or MAPK 10 minutes after anti-CD3 
(1.0 µg/mL) stimulation was measured using flow cytometry with gating on CD4+ T 
cells. Purified CD4+ T cells were exposed to control RNA or Env-expressing 293T cells 
and activated using anti-CD3 in the absence of IL-2. Two days later, cells were 
stimulated with 20 U/mL IL-2 and analyzed for STAT5a phosphorylation 7 minutes later. 
CD4+ T cells exposed to IIIB Env-transfected 293T cells and stained with isotype control 
mAb (shaded gray) or specific phosphoprotein mAb (thin line) or specific 
phosphoprotein mAb-stained control-transfected 293T cells (thick line) are shown for 
each signaling molecule. Experiments shown are representative of 3 independent 
experiments. 
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Env expressed on free virions suppresses CD4+ T cell proliferation 
	  	  	  	  	  	  	  	  	  	  	  	  	  In HIV infection, Env present on infected cells and free virions can contact CD4+ 
T cells and induce dysfunction 55. Above, we demonstrate that Env expression on cells as 
occurs during vaccination with encoding vectors such as DNA or viruses induces an 
inhibition to antigen-specific CD4+ T cell proliferation in a CD4 dependent manner. This 
system used human PBMC as a source of CD4+ T cells that were cultured with Env 
expressing mRNA transfected 293T cells or vaccinia infected DC in the presence of 
either anti-CD3 or superantigen (TSST-1) stimulation. To test whether Env on virions is 
also able to induce suppression of anti-CD3 stimulated CD4+ T cell proliferation, we 
incubated PBMC with increasing amounts of AT-2 inactivated HIV-1 (NL4-3), which is 
infection deficient, but retains a functional (able to bind CD4) Env, modeling the 
noninfectious interactions between circulating free virions and CD4 in HIV infection 112. 
We found that inactivated virus could inhibit anti-CD3 stimulated CD4+ T cell 
proliferation in a dose dependent manner, which was overcome by sCD4 (Figure 2.5A-
	   38	   	   	  
B), similar to that observation for Env expressed on cells. Variability in the amount of 
suppression was observed for different preparations of AT-2 virus ranging from 29% 
(Figure 2.5A-B) to greater than 60% (data not shown). Decreased fluorescence intensity 
of anti-CD4 SK3 mAb staining for virion-incubated PBMC 14 verified a functional 
interaction between CD4 and Env (data not shown). Interestingly, we found that 
proliferation of CD4 negative cells was also abrogated after incubation with 1 µg/ml 
virions (Figure 2.5A), which might be due to impairment of CD4+ T cell helper functions 
by Env, leading to decreased growth cytokine production (IL-2 and others) and less 
activated APCs in PBMC that, in turn, cause a decrease in antigen-stimulated CD8+ T 
cell proliferation. 
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Figure 2.5 
 
 Figure 2.5. HIV Env present on free virions induces suppression of anti-CD3 
stimulated CD4+ T cell proliferation through CD4 binding. Freshly isolated human 
PBMC were CFSE labeled and exposed to AT-2-treated HIV-1 virions (A and B) in the 
presence or absence of sCD4 (10 µg/ ml). The cultures were stimulated with anti-CD3 
mAb and IL-2. Four days after Env exposure and stimulation, PBMC were stained for 
CD4 and the proliferation of CD4+T cells was monitored by flow cytometry (A). The 
percent of input CD4+ T cells that proliferated (B) was calculated as described 164. Data 
are representative of three experiments.  B, 1=p <0.05.  p-values calculated using 2-tailed 
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homoscedastic student’s t-test comparing AT-2 virus-treated CD4+ T cell proliferation to 
no virus treated. 
 
CD25+ Treg cells are not required for Env induced suppression   
          We then investigated whether Treg cells are involved in Env induced suppression 
in our system. CFSE stained total or CD25 depleted PBMC were cultured with Env-
expressing or control 293T cells in the presence of anti-CD3 and IL-2 stimulation. CD25 
staining verified that more than 95% of CD25+ cells were successfully removed from 
PBMC (Figure 2.6A). As expected, CD25 depletion significantly enhanced the 
proportion of proliferating CD4+ T cells in both Env exposed (From 8.1% to 18%) and 
control cultures (From 13% to 32.7%, Figure 2.6B). However, exposure to Env caused 
almost a 50% decrease in the proportion of proliferating CD4+ T cells in CD25 depleted 
PBMC (From 18% to 32.7%, Figure 2.6B), suggesting that pre-existing CD25+ Treg cells 
were not required for Env induced suppression of CD4+ T cell proliferation.  
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Figure 2.6 
 
Figure 2.6. CD25+ Treg cells are not required for Env-induced suppression of 
proliferation. CD25+ cells were depleted from human PBMC using two rounds of CD25 
magnetic beads. Flow cytometric analysis demonstrated depletion of greater than 95% of 
CD25+ cells (A). CFSE labeled whole (top, B) or CD25-depleted (bottom, B) PBMC 
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were exposed or not to IIIB Env-expressing 293T cells in the presence of anti-CD3 and 
IL-2 stimulation. CD4+ T cell proliferation 4 days after Env exposure is shown. (C) The 
percent of input CD4+ T cells that proliferated is shown for each condition in B. 
1=p<0.01. p-values were calculated using a 2-tailed homoscedastic student’s t test 
comparing Env-treated CD4+ T cell proliferation to no virus-treated. Data are 
representative of at least four repetitions. 
 
Effect of Env on frequency of CD4+, CD25+, FoxP3+ cells in PBMC 
           We show that CD25+ Treg cells are not required for Env to induce suppression of 
CD4+ T cell proliferation. One important question that remains highly controversial is 
whether and how HIV, or its associated gene products, regulates Treg cells. Both 
increased and reduced frequency of Treg cells have been reported in HIV+ patients 
compared to uninfected people 1, 149, 161. To test whether Env, as the major surface antigen 
of HIV interacting with CD4+ T cells, directly induces or activates Treg cells, we first 
determined and compared the percentage of CD4+, CD25+, FoxP3+ cells in both 
stimulated and resting human PBMC with or without exposure to Env expressed on 293T 
cells. Compared to resting PBMC, stimulation caused a one- to two-fold increase in the 
amount of CD4+, CD25+, FoxP3+ T cells in PBMC at all time points studied (Figure 
2.7A), which is consistent with a study demonstrating activation induced FoxP3 
expression in human T cells 60. Of importance, for both resting and stimulated PBMC, 
Env exposure did not induce significant changes in the percentage of CD4+, CD25+, 
FoxP3+ T cells (Figure 2.7A). Analyses of T cell proliferation in the activated cells 
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demonstrated a significant reduction of CD4+ T cell division when cultured with Env 
mRNA transfected 293T cells, verifying Env expression on 293T cells and its inhibitory 
effect.  
 
           We then investigated whether Env present on free virions affected the percentage 
of FoxP3+ Treg cells in PBMC, as we observed inhibition of CD4+ T cell proliferation by 
free virions (Figure 2.5A-B). PBMC were incubated with AT-2 inactivated HIV-1 virions 
at 1 µg/ml p24 gag protein equivalent for various period of time. Surface and intracellular 
staining demonstrated no significant difference in the number of CD4+, CD25+, FoxP3+ 
cells between virion incubated and control PBMC at all studied time points (days 1, 3 and 
5) (Figure 2.7B), which is in contrast with the observation that exposure of purified CD4+ 
T cells to AT-2 treated HIV resulted in significantly increased FoxP3 expression at both 
mRNA and protein levels, resulting from Env induced enhancement in cell viability and 
consequent accumulation of FoxP3+ cells 112. Taken together, our data suggested that 
neither Env delivered on cells as would be found during infection or after encoding 
vector delivery as part of a vaccine nor Env present on free virions could directly induce 
or activate T regulatory cells in resting or stimulated PBMC.  
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Figure 2.7 
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Figure 2.7. Effect of Env delivered by cell surface expression or on virions on 
FoxP3+, CD25+, Treg cells in unstimulated and stimulated PBMC. Unstimulated or 
anti-CD3 stimulated PBMC were analyzed by flow cytometry for CD25 and FoxP3 
expression on CD4+ T cells at days 1, 3, and 5 after exposure to HIV Env expressed by 
293T cells (A) or AT-2-treated virions (B). Histograms shown are gated on live 
CD4+cells. Data are representative of at least four repetitions. 
 
IL-10 and TGF-β  production in Env exposed PBMC  
           Immune suppression mediated by Treg cells can occur through either cell contact 
or suppressive cytokines, particularly IL-10 and TGF-β 31, 156. To test whether Env 
exposure, rather than inducing an increased number of FoxP3+ cells, stimulates an 
enhanced production of IL-10 and/or TGF-β by Tregs, supernatants of cultures with and 
without Env exposure were collected at various time points (days 1, 3, and 5) after 
initiation of co-culture, followed by quantitation of IL-10 and TGF-β by ELISA. TGF-β 
was persistently undetectable at any of the studied time points in both Env exposed and 
control supernatants. Significant amounts of IL-10 were produced and accumulated in the 
supernatants starting at 12 hours after stimulation. However, no difference was observed 
in the amount of IL-10 production between Env-exposed and control cultures (Figure 
2.8). Considered together, these data suggest that Env does not induce a more activated 
phenotype of Treg cells leading to increased suppressive cytokine production.  
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Figure 2.8 
 
Figure 2.8. Effect of Env exposure on IL-10 production. 293T cells expressing IIIB 
Env or control transfected were cultured with PBMC in the presence or absence of anti-
CD3 and IL-2 stimulation. Supernatants were collected at the indicated time points, and 
supernatant associated IL-10 was determined by ELISA. Data are representative of at 
least five experiments. Error bars are the SEM for triplicate measurements.  
 
Env does not enhance suppressive activity of CD4+, CD25+, CD127- T cells  
          We demonstrate that Env induces neither an increased number of CD4+, D25+, 
FoxP3+ cells nor an enhanced IL-10 and TGF-β production in PBMC and their depletion 
does not negate Envs ability to suppress CD4+ T cell proliferation. To test whether Env 
activates Treg cells, resulting in an enhanced suppressive activity independent of IL-10 or 
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TGF-β, an in vitro suppression assay was developed in which Treg cells isolated from 
Env exposed and control PBMC were cultured with autologous responder cells in the 
presence of anti-CD3 stimulation. The suppressive activity of Treg cells, on a per-cell 
basis, was evaluated by their capacity to inhibit anti-CD3 stimulated responder cell 
division. In addition to CD25, CD127, a subunit of the IL-7R, has also been shown to be 
a useful cell surface marker for defining Tregs. We sorted Tregs from control RNA or 
Env RNA transfected 293T cell exposed PBMC based on CD4+, CD25+, and CD127- 
expression94. Greater than 90% of the sorted cells expressed FoxP3 (Figure 2.9A). In 
addition to natively expressed FoxP3 in a subset of CD4+ T cells in PBMC, an additional 
population of FoxP3+ cells appears after activation. These cells are derived from FoxP3-, 
CD4+ cells and their ability to suppress immune responses is controversial 60. We 
attempted to use this same sorting strategy to isolate Tregs after Env exposure and anti-
CD3 stimulation, but it should be noted that activation induces up-regulation of CD25 as 
well as down-regulation of CD127 on non-Treg CD4+ T cells, making the isolation of 
FoxP3+ cells less accurate. However, approximate 30-50% of the sorted cells from 
stimulated PBMCs expressed FoxP3 (data not shown). 
 
           Sorted CD4+, CD25+, CD127- suppressor cells inhibited responder CD4+ T cell 
divisions in a dose dependent manner (Percentages of proliferating CD4+ T cells as the 
proportion of CD4+ T cells are 48% and 74% for Suppressor: Responder ratio of 1:3 and 
1:6, respectively) (Figure 2.9B-C). However, Env-exposed and control CD4+, CD25+, 
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CD127- T cells were equally suppressive, since no significant difference in the proportion 
of dividing responder cells was found between them (Figure 2.9B-C).  
 
            We then determined whether Env induces a more suppressive activity of 
activation induced FoxP3+ cells by sorting CD4+, CD25+, CD127- T cells from PBMC, 
which were first depleted of CD25+ cells and then co-cultured with 293T cells and 
activated by anti-CD3. Activation induced CD4+, CD25+, CD127-T cells (approximately 
30-50% FoxP3+), although less suppressive than naturally FoxP3+ cells isolated from 
unstimulated total PBMC, also inhibited CD4+ T cell proliferation in a dose dependent 
manner (Figure 2.9D-E). Of importance, no difference in suppressive ability between Env 
exposed and control activation-induced Treg cells was observed (Figure 2.9D-E). Taken 
together, these data indicate that Env exposure does not enhance the functional 
suppressive activity of either pre-existing Treg or activation induced FoxP3+ cells. 
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Figure 2.9 
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Figure 2.9. Endogenously present or activation induced (plus FoxP3, CD25) FoxP3!  
Treg cell suppressive activity is not modulated by Env. (A) Isolation of FoxP3+ Treg 
cells from PBMC using CD4, CD25, and CD127. CD4+ live lymphocyte sized cells (gate 
in left panel of A) were sorted for high CD25 and no CD127 expression (gate in middle 
panel of A). The sorted cells were stained for FoxP3 (A, right panel) and demonstrated 
greater than 90% positivity. (B) As a source of suppressors, PBMC were cultured with 
Env expressing or control 293T cells, followed by isolation of CD4+, CD25+, CD127- T 
cells by flow cytometric sorting (detailed in A) 48 h after Env exposure. CFSE-labeled 
responder cells (autologous PBMC depleted of CD25+ cells) were cocultured with graded 
numbers of sorted CD4+, CD25+, CD127- suppressor cells in the presence of anti-CD3 
and IL-2 stimulation. CFSE intensity of responder cells with CD4 staining was monitored 
by flow cytometry at day 4 to quantify responder cell proliferation. (C) Percent of input 
CD4+ T cells that proliferated was calculated for each condition. 1=p < 0.007. p-values 
calculated using 2-tailed homoscedastic student’s t-test comparing 293T Env-treated 
CD4+ T cell proliferation to no Env-treated. (D) As a source of suppressors, CD25-
depleted PBMC were cultured with Env expressing or control 293T cells in the presence 
of anti-CD3 and IL-2 stimulation, followed by isolation of CD4+, CD25+, CD127- T cells 
48 h after stimulation, as described in A. CFSE-labeled responder cells (autologous 
PBMC depleted of CD25+cells) were cocultured with graded numbers of sorted CD4+, 
CD25+, CD127- suppressor cells in the presence of anti-CD3 and IL-2 stimulation. CFSE 
intensity of responder cells with CD4 staining was monitored by flow cytometry at day 4 
to quantify responder cell proliferation. (E) Percent of input CD4+ T cells that 
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proliferated was calculated for each condition. 1=p < 0.009. p-values calculated using 2-
tailed homoscedastic student’s t-test comparing 293T-Env-treated CD4+ T cell 
proliferation to no Env-treated. Data are representative of at least three repetitions. 
 
Discussion 
           The system studied here models the encounter of CD4+ T cells with both APCs 
and non-APCs expressing Env delivered as a vaccine, the interaction between CD4+ T 
cells and infected cells in an HIV-infected individual, and the interaction between Env 
expressed on a virion and CD4+ T cells. Both X4 and R5 Envs suppressed the activation 
and proliferation of CD4+ T cells via specific interaction with CD4. Suppression was 
characterized by a lack of proliferation despite normal activation of the main signaling 
pathways involved in T-cell activation and proliferation, AKT, MAPK, and STAT5a but 
a deficient upregulation of early and late cell-surface activation markers. The suppression 
of antigen-induced proliferation was not due to IL-2-dependent anergy, apoptosis, or cell 
death.  
 
            The role of CD4 versus the coreceptors CXCR4 and CCR5 in mediating Env-
induced suppression is controversial 7, 15, 71, 154. Some reports have suggested a role for 
coreceptors in mediating suppression in conjunction with CD4 15, 154. Others have 
suggested that Env can mediate suppression solely via CD4 or coreceptors7, 71{Arthos, 2002 
#110, In this  study, we show that Env delivered as a vaccine, as a component of an 
infected cell, or as part of a virion mediates a suppression of activation and proliferation 
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regardless of its coreceptor usage. Although CD4 interaction is required for this 
suppression, both coreceptors could have played a role. To test this, we examined 
suppression of X4 Envs in the presence of AMD3100, which blocks Env interaction with 
CXCR4 45. AMD3100 caused a non-specific increase in proliferation in both Env and 
control transfected 293T-exposed CD4+ T cells, which may be attributed to blocking 
inhibitory chemokine signaling through CXCR4155. Similar studies with TAK-779 9, 
which blocks R5 Env interaction with CCR5, did not overcome suppression. This 
suggests that in our system studying Env in the absence of HIV infection, inhibition of 
CD4+ T cell proliferation occurred in a CD4-dependent, chemokine receptor-independent 
manner.   
 
Previous studies demonstrating the suppressive effects of Env have focused on a 
single aspect of CD4+ T cell suppression such as apoptosis or anergy and used systems to 
model interactions that occur during HIV infection. In this chapter, I present a 
comprehensive study examining multiple facets of Env-induced suppression when it is 
used as an immunogen, present on a virion, or expressed in a manner that models HIV-
infection of cells. DCs that acquire a vaccine containing HIV Env will express protein 
from all the delivered antigens. When the protein is processed and presented to antigen-
specific CD4+ T cells by the APCs, suppression by surface-expressed Env would occur, 
thus hindering immune responses to all antigens in the cocktail. Because Env is an 
essential component in an HIV vaccine that aims to generate neutralizing antibodies, 
inclusion of nonsuppressive forms of Env will enhance immune responses. 
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           Accumulating studies have implicated the involvement of CD25+ Treg cells in the 
inhibition of anti-HIV CD4+ and CD8+ T cell responses in HIV infection 1, 5, 52, 85, 86, 112, 
161. The part of thesis was also designed to address three questions: 1) whether HIV virion 
expressed Env, like that expressed on the cell surface, induces inhibition of polyclonally 
stimulated CD4+ T cell proliferation; 2) whether Treg cells are responsible, at least in 
part, for Env induced suppression; and 3) whether Env is able to directly induce, or 
activate, Treg cells. The answers to these questions are critical to determine whether the 
frequency and function of Treg cells are regulated through direct interaction with virus, 
and how this regulation of Treg cells relates to dysfunction of T cell immunity in HIV 
infection. Here, I demonstrate that Env expressed on either virions or cells induces 
suppression of CD4+ T cell activation, and that Env does not induce or activate Treg cells 
as a mediator for this inhibition.  
 
 In HIV infection, in addition to infected cells, circulating free virions also bear 
functional trimeric Env. Although protease-defective, gp120-containing HIV-1 particles 
were reported to induce apoptosis in human peripheral blood T cells, whether such 
virions use Env, like its counterpart expressed on cells, to induce inhibition to CD4+ T 
cell proliferative responses remains unclear 79. Using AT-2 inactivated HIV-1 viral 
particles that are non-infectious but maintain integrity of functional Env 112, 131. I 
demonstrate that Env on HIV virions inhibits CD4+ T cell proliferation through gp120-
CD4 signaling.  
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           HIV impairs host CD4+ T cell immunity through multiple mechanisms. Although 
the involvement of Treg cells in suppressing anti-HIV specific T cell responses has been 
documented in a growing body of literature, there is controversy as to whether HIV, or its 
gene products, inhibits host CD4+ T cell activation through the direct induction or 
activation of Treg cells. An interaction between Treg cells and HIV through gp120-CD4 
signaling has been proposed 112, which provides a basis for our in vitro system where 
human PBMC, as source of CD4+ T cells, were exposed to Env expressing 293T cells or 
AT-2 inactivated virions, modeling the in vivo interaction between Env and CD4+ 
effector as well as CD4+ Treg cells, during an immune response. In this thesis, I show 
that depletion of pre-existing CD4+, CD25+ Treg cells from PBMC increases the 
proliferation of polyclonal TCR stimulated CD4+ T cells, which is consistent with 
observations in HIV infected patients that virus exposed Treg cells maintain suppressive 
activity. However, Env-induced inhibition remained in the absence of CD25+ Treg cells, 
strongly suggesting that Treg cells are not functionally involved in Env-induced 
suppression. This result implies that the suppressive effect of Treg cells on anti-HIV T 
cell responses, which has been observed in HIV infected patients, may be a general 
feature of Treg cells.  
 
            The regulation of Treg cells in HIV remains highly controversial. Studies using 
peripheral blood reported increased 1, 149, 161 as well as reduced 49, 115 numbers of Treg 
cells in HIV infection. In contrast, later studies using LN or gastrointestinal mucosa of 
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infected patients demonstrated up-regulation of FoxP3 and other markers of Treg cells, 
supporting Treg accumulation in the tissue at sites of viral replication 5, 6, 52, 112. Factors 
including markers used to identify Treg cells, disease stage in selected patients, and ART 
treatment, might contribute to the various findings from different studies. Our results 
demonstrate that regardless of the form of Env delivery (Env-expressing cells as would 
be observed during infection or after encoding vaccine delivery or free virions) and 
stimulation status of T cells, the percentage of FoxP3+, CD25+, CD4+ T cells was not 
affected by Env, which is in contrast to the observation that an increase in FoxP3+ cells 
was detected in CD4+ T cells after exposure to AT-2 inactivated virions, resulting from 
Env induced enhancement in Treg cell viability 112. The difference in cells used (PBMC 
vs purified CD4+ T cells) could have contributed to the different results in these two 
studies. The purification of CD4+ T cells could have increased their level of apoptosis, 
which was blunted by Env acting on Tregs or increased by Env acting on non-Treg CD4+ 
T cells. We observed a low level of apoptosis in our unstimulated PBMC with no 
difference between Env exposed and control (data not shown). Although, if this were the 
case, we would have expected to see a difference after anti-CD3 stimulation (Figure 
2.7A), which increases apoptosis. 
 
              It has been reported that, unlike murine Foxp3- T cells, a subset of human 
FoxP3- T cells could be induced to transiently express FoxP3 upon activation 60, 98. In 
agreement with these studies, we found that anti-CD3 stimulation induced increased 
FoxP3 expression in CD4+ T cells, peaking approximately 48 hours after activation (data 
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not shown). Furthermore, we measured FoxP3 expression in CD25-depleted PBMC, and 
found that activation induced FoxP3 expression, which is in agreement with a published 
report 53. These activation induced FoxP3+, CD4+ T cells have suppressive activity on T 
cell proliferation, but this activity was not modulated by Env exposure.  
 
            One of the functional characteristics of Treg cells is its capacity to suppress 
antigen specific CD4+ and CD8+ T cell proliferation in a dose-dependent manner 156. 
Since FoxP3 is expressed intracellulary, several surface antigens in addition to CD25 
have been identified as alternative markers for isolation of Treg cells, one of which is 
CD127, a subunit of the IL-7R94. Analysis of sorted CD4+, CD25+, CD127- T cells, which 
contained 90% FoxP3+ cells, demonstrated that Env exposure did not alter the 
suppressive activity of peripheral blood Treg cells, which is consistent with a previous 
finding that Treg cells exposed to AT-2 treated HIV virions are equally suppressive 
compared with untreated Treg cells 112.  
 
             In summary, I used models of the encounter of CD4+ T cells with both APCs and 
non-APCs expressing Env and virion expressed Env to study Env mediated suppression 
of CD4+ T cell proliferation. Both X4 and R5 Envs suppressed the activation and 
proliferation of CD4+ T cells via specific interaction with CD4. Suppression was 
characterized by a lack of proliferation despite normal activation of the main signaling 
pathways involved in T cell activation and proliferation, AKT, MAPK, and STAT5a but 
a deficient upregulation of early and late cell surface activation markers. The suppression 
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of antigen-induced proliferation was not due to IL-2 dependent anergy, apoptosis, or cell 
death. My data also demonstrates that HIV Env neither induced nor activated Treg cells, 
and that CD25+ Treg cells are not responsible for Env induced suppression of CD4+ T 
cell proliferation. Our findings do not demonstrate that HIV does not regulate Treg 
number or function, only that Env binding does not, in model in vitro assays. Treg cells 
could still be depleted by direct infection or bystander effects or their number increased 
by other gene products or downstream effects of infection, such as chronic immune 
stimulation. Further work is needed to elucidate the in vivo regulation of Treg cells and 
their physiological relevance in the context of HIV infection and vaccination.  
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CHAPTER 3 
In vivo analysis of immune and viral responses in retroviral suppressed 
SIV infected rhesus macaques  
Introduction 
CD4+ T cells play a central role in maintaining effective cellular and humoral 
immune responses by providing help to CD8+ T cells, B cells and innate effectors. One of 
the hallmarks of HIV infection is the progressive loss of CD4+ T cells and their 
associated antigen-specific responses. This is characterized as both a decline in the 
number of CD4+ T cells and an early loss of the functional activity of cells with certain 
antigenic specificities 41, 90, 105. In particular, HIV antigen-specific CD4+ T cell responses 
are dysregulated to a greater extent than responses to other common antigens 88, 91, 158.  It 
has been demonstrated that chronically HIV-1 infected progressing patients fail to mount 
a potent HIV-specific CD4+ T cell response even in the setting of viral suppression by 
ART.  Immunization of chronically infected ART treated patients with HIV antigens 
leads to poor HIV-specific responses50.  The mechanisms for the inability to generate 
HIV-specific CD4+ T cell responses in chronic infection are not fully characterized or 
understood.  
 
To initiate an immune response, DC bearing antigens interact with antigen-
specific CD4+ T cells that migrate through lymphoid tissue, leading to CD4+ T cell 
activation and expansion.  Signals from the DC induced by the pathogen instruct the type 
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of T cell response, characterized as Th1, Th2, Th17, Tr1, and Th3/Tr2 12, 36, 64.  However, 
in the presence of HIV, the interaction between DC and CD4+ T cells enhances viral 
replication by multiple mechanisms 168. It has been demonstrated that even in the 
presence of potent regimens of viral suppression, a very low level of viral production 
could still be detected 43, 70, 122. It is generally believed that this viral replication does not 
represent acute infection of cells, as no sequence evolution is observed 32, 84, 122, but the 
source of the low level of virus may be derived from DC mediated activation of latent 
virus in memory T cells or other reservoirs 126.  
 
I use a macaque model of HIV-infected individuals treated with ART during 
chronic infection to study the effect of SIV antigen stimulation in lymph nodes early after 
immunization.  CMV seropositive rhesus macaques were infected with SIVmac251 and 
after 4 months, treated with D4T and PMPA to artificially control viral loads. Animals 
were immunized in both arms and legs with SIV or CMV antigen, which allowed 
draining lymph nodes for each antigen to be obtained from the same animal at the same 
time, allowing a direct comparison of the effect of SIV and CMV antigen stimulation 
(Figure 3.1). Immunologic and virologic responses were measured in draining lymph 
nodes and peripheral blood to analyze differences in responses induced by an SIV antigen 
compared to a control immunization. 
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Materials and Methods 
Ethics statement 
           All animal experiments were performed in strict accordance with good animal 
practice following guidelines for relevant national and regional animal welfare bodies.  
The studies were approved by the University of Pennsylvania and Tulane Institutional 
Animal Care and Use Committees (IACUC).  
 
Immunogens 
           Plasmid DNA expressing the SIV Gag core protein from Mac239 (pSIVgag) was 
used. It is a Rev-independent expression vector that has been codon optimized for a high 
level of expression, as previously described 20. Plasmid DNA expressing the Rhesus 
CMV pp65 protein was used 170. DNA was formulated in 0.15 M citrate buffer and 0.25% 
bupivicaine at a pH of 6.5. 
 
Infection of rhesus macaques and overview of study 
            The animal study timeline is shown in Figure 3.1. Three CMV seropositive 
Mamu-A*01 positive rhesus macaques were intravenously infected with SIVmac251 at 
time zero. Four months after SIV infection, ART was introduced (SQ PMPA 20 mg/kg 
qD and PO D4T 10 mg/kg qD) and continued until the end of the experiment. The 
macaques were followed for 4 months on ART for recovery of periphery CD4+ T cell 
count and viral load suppression. Eight months after infection and 4 months after the 
initiation of ART, each monkey received 2 immunizations with SIV gag encoding DNA 
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i.m. (2 mg per injection), one in the left arm and one in the left leg and 2 immunizations 
with CMV pp65 encoding plasmid (2 mg/injection) in the right arm and leg. After 
immunization, draining lymph nodes were sampled at two-time points for each animal by 
first removing inguinal LNs on each side followed by axillary LN removal from both 
sides (FH40 - D3 and D9, DD05 - D5 and D11, and CT64 - D7 and D14). We were 
unable to collect pre-immunization LNs due to technical limitations. D60 LNs were 
collected as no-immunization control. PBMC and plasma samples were collected every 2 
to 4 weeks throughout the experiment.  
 
Measurement of peripheral viral load and CD4+ T cell counts 
          Viral RNA in plasma was quantified by a bDNA signal amplification assay from 
Bayer Inc., version 4.0, specific for SIV, which has a threshold detection limit of 125 
viral copies per ml plasma 151. 
 
           CD4+ T cell counts using whole blood collected in EDTA were analyzed with anti-
CD3 (Biosource International, Camarillo, CA), anti-CD4 and anti-CD8 staining (anti-
Leu3a and anti-Leu2a, Becton Dickinson, San Jose, CA) as previously described 35.  
 
PBMC isolation and LN biopsy  
            Peripheral blood lymphocytes were isolated from EDTA-blood using Ficoll-
diatrizoate gradient centrifugation and analyzed for CD4’s by flow cytometry or 
cryopreserved in 90% FCS 10% DMSO. LNs were obtained under anesthesia. The LNs 
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were teased carefully to generate single-cell suspensions. The single-cell suspensions 
from lymph nodes were divided into two parts; one was cryopreserved and stored in 
liquid nitrogen and one was frozen as a pellet. 
   
In vitro stimulation  
            Cryopreserved LN cells or PBMC were thawed and washed twice with pre-
warmed complete RPMI 1640 supplemented with 10% heat-inactivated FCS (HyClone) 
and L-glutamine (Invitrogen Life Technologies). Cells were resuspended in complete 
RPMI medium and rested for two hours at 37°C before being washed again and used. 
Unless otherwise noted, cells were prepared at concentration of 1 x 106 cells/ml for in 
vitro stimulation. For characterizing the SIV- and CMV-specific T cell responses, LN 
cells or PBMC were incubated with either an SIVmac239 gag 15-mer peptide pool with 
11-amino acid overlap, 2 µg/ml each peptide (NIH AIDS Research and Reference 
Reagent Program, Bethesda, MD) or a rhesus CMV pp65 peptide pool (15-mers 
overlapping by 11 amino acids) at 2 µg/ml for each peptide 170 at 37°C for 6 hours in the 
presence of Golgi-Stop (0.7 µg/ml) and Golgi-Plug (1 µg/ml) and 1 µg/ml of co-
stimulatory antibodies anti-CD28 and anti-CD49d (BD Bioscience, CA).  Negative 
controls with no stimulation and positive controls with PMA/Ionomycin (50 ng/ml, 
Sigma-Aldrich) were used.  
 
Cell staining  
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           After 6 hours of stimulation, cells were first washed with 2 ml PBS containing 1% 
FCS and stained with aqua blue dye for cell viability (Invitrogen, Eugene, OR). Cells 
were then stained with pre-titrated amounts of fluorochrome-conjugated surface staining 
antibodies (anti-CD4-PerCP Cy5.5, anti-CD8-FITC, anti-CD14-Pac Blue, anti-CD16-Pac 
Blue, and anti-CD95-PE-Cy5, anti-CD20-Pac Blue (eBioscience), and anti-CD28-ECD 
(Bechman Coulter)) and incubated at 4°C for 20 minutes. Cells were then washed and 
fixed in 250 µl BD Fixation/Permeabilization solution (BD Biosciences) for 20 minutes 
at 4°C. After fixation, cells were permeabilized with 1 x BD Perm/Wash buffer and 
stained with pre-titrated fluorochrome-conjugated antibodies (anti-CD3-APC-Cy7, anti-
IL-2-PE, anti-IFN-γ-APC, anti-TNF-α-PE-Cy7 (BD Biosciences) at 4°C for 45 minutes. 
Cells were then washed with Perm/Wash buffer and re-suspended in 300 µl PBS 1% 
FBS.  
 
Flow cytometric analysis 
            Cells were analyzed by polychromatic flow cytometry on an LSRII (BD 
Biosciences) equipped for the detection of 18 fluorescence parameters. In this study, for 
all 12-color flow analyses, 200,000 to 500,000 events were acquired for each sample. 
Antibody capture beads (BD Biosciences) stained separately with individual mAbs were 
used to conduct electronic compensation. Flow Jo version 8.8.7. (Tree star, Ashland, OR) 
was used to analyze the polychromatic flow data with all the analytic gating as described 
before16, 25. Single cells were gated according to Forward Scatter Height (FSC-H) and 
Forward Scatter Area (FSC-A). Dead cells, B cells, NK cells, and monocytes were 
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excluded based on staining with aqua blue LIVE/DEAD fixable violet dead cell stain or 
CD14, CD16 and CD20 staining.  Lymphocytes according to FSC-A and SSC-A, CD3+, 
CD3+CD4-, and CD3+CD4+ were sequentially selected for cytokine analysis. Expressions 
of IL-2, TNF-α and IFN-γ were identified in CD3+CD4- and CD3+CD4+ T cell 
populations. In CD3+ lymphocyte population, memory and naive cells were identified 
through CD28 and CD95 staining as previously described 16, 25. 
 
RNA extraction and quantitative PCR 
               Total RNA from LN mononuclear cells was extracted using Trizol according to 
manufacturer’s instruction (Invitrogen) and subject to real-time PCR on an ABI 7500 
(Applied Biosystem, Carlsbad, CA). Doubly spliced, singly spliced, and unspliced SIV 
viral RNA and the housekeeping gene GAPDH were analyzed. The primers and MGB 
probes specific for these genes were obtained from Applied Biosystem (Table 4). 
Changes in the expression of individual viral RNAs with GAPDH normalization were 
calculated utilizing delta cycle threshold (ΔCT) values, and the comparisons were made 
between LNs draining SIV and CMV immunizations from the same animal collected at 
the same time on the indicated days post immunization.  
   Levels of IFN-γ mRNA were quantitated by RT-PCR against a standard curve 
derived from serial dilutions of in vitro made transcripts, using primers and probe listed 
on Table 4. Copies of IFN-γ mRNA were expressed per 1 µg of RNA.  
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Statistics 
                 Mean, Standard deviation, and student’s t-test were performed using Microsoft 
Excel software. 
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RESULTS 
PART 1 
Infection and immunization of rhesus macaques and study overview 
            Pathogenic SIVmac251 infection of rhesus macaques has been well described for 
studying viral dynamics, immune responses, and anti-retroviral therapy 102, 103, 107, 114, 153, 
159. All animals were Mamu A*01 positive to reduce MHC variation in disease course 
and T cell responses and naturally infected with Rhesus CMV. The study was designed to 
infect animals (1000 TCID50 of SIVmac251 by intravenous injection) and allow them to 
reach steady state viral loads (4 months) followed by ART treatment (PMPA and D4T) 
for 4 months. Animals were then immunized with expression plasmids encoding non-
mutated SIV gag or rhesus CMV pp65 in both arms and legs and lymph nodes draining 
either SIV gag or CMV pp65 plasmid injections from the same animal at the same time 
were obtained 3, 5, 7, 9, 11 and 14 days post immunization (Figure 3.1). Serum and 
PBMCs were obtained every 2 to 4 weeks throughout the experiment. 
Figure 3.1 
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Figure 3.1. Experimental protocol for infection and immunization of rhesus 
macaques. Mamu A*01 positive rhesus macaques naturally infected with rhesus CMV 
were intravenously inoculated with SIVmac251, followed by ART treatment (DT4 and 
PMPA) from days 119 post infection through the end of experiment. On days 286 or 290 
post infection, monkeys received 2 immunizations with SIV gag encoding DNA i.m. (2 
mg per injection), in the left arm and left leg, and 2 immunizations with CMV pp65 
encoding DNA i.m. (2 mg per injection) in the right arm and leg. LN and PBMC were 
collected from the immunized animals. 
PART 2 
Establishment of chronically SIV-infected rhesus macaque with retroviral 
suppression and CD4+ T cell recovery by ART 
ART suppresses viral replication leading to recovery of peripheral CD4+ T cell counts 
   SIV infection was established in all three animals with kinetics typical of SIV 
replication during primary infection in naïve rhesus macaques (Figure 3.2A) 68, 143. 
Introduction of ART 4 months post infection, when set point viral loads had been 
established, efficiently suppressed viral replication to undetectable levels.  One macaque 
demonstrated occasional blips in viral load but returned to undetectable levels after each 
without any change in therapy (Figure 3.2A). 
 
 Absolute CD4+ T cell counts in the peripheral blood demonstrated increases after 
introduction of ART in all animals with sustained levels of more than 500 cells/µl (Figure 
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3.2B). These findings demonstrate that chronic SIV infection was achieved and ART 
successfully suppressed viral replication leading to recovery of peripheral CD4+ T cell 
counts.  
 
 Figure 3.2 
  
 
Figure 3.2. Summary of viral loads and peripheral CD4+ T cell counts in rhesus 
macaques.	  Viral loads and CD4 counts were measured every 2 to 4 weeks throughout the 
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experiment. (A) Viral RNA in plasma was quantified by a bDNA signal amplification 
assay and expressed as RNA copies per ml plasma. ART treatment controlled the viral 
loads in all three animals. (B) Peripheral CD4+ T cell counts increased after the initiation 
of ART. Macaque blood samples were stained for anti-CD3, anti-CD4, and anti-CD8 
antibodies and the number of CD3+, CD4+ T lymphocytes were determined by flow 
cytometry. CD4+ T cell counts were expressed as CD4+ T cells per µl blood. 
 
PART 3  
Immunization induced immunologic responses in draining lymph nodes  
3.1. Immunization-induced immune activation in draining LNs         	  
  Animals were immunized with SIV gag encoding DNA in the arm and leg on one 
side and CMV pp65 encoding DNA on the other side at the same time. LNs, one draining 
an SIV immunization and one draining a CMV immunization, were excised from each 
animal at 2 time points post immunization. All comparisons were made between LNs 
from the same animal obtained at the same time that differed only in whether they 
drained an SIV or a CMV immunization. I was unable to obtain LNs prior to 
immunization due to limitations on the number of surgeries in a short time period. I 
obtained LNs from both the left and right sides of all animals 60 days post immunization. 
The measurement of immune responses did not demonstrate any difference between LNs 
draining HIV gag or CMV pp65 and these LNs were assumed to represent preimmune 
conditions.	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LN mononuclear cells were assessed for the amount of IFN-γ mRNA, a major 
effector cytokine for adaptive immunity, as a measurement of total immune activation 
induced by immunization. The expression of IFN-γ was maximal 3 days post 
immunization in LNs draining both SIV gag and CMV pp65, which was followed by a 
decline at day 5 and a decrease in IFN-γ expression to the levels observed in 60 day post 
immunization LNs (Figure 3.3.1). 	  
	  
Figure 3.3.1	  
	  
Figure 3.3.1.  Total IFN-γ  mRNA expression in LNs. Total RNA from LN 
mononuclear cells draining either SIV-gag or CMV-pp65, collected on indicated days 
post immunization were subject to real-time PCR with IFN-γ specific primers and probes 
for absolute quantitation of macaque IFN-γ RNA expression. The results were 
normalized and expressed as the RNA copy number per µg total RNA. The comparisons 
between SIV- and CMV-immunization were made in LNs collected from the same 
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animal at the same time on indicated days. The difference on Day 3 was significant with 
a p=0.036 noted by a *.    	  
	  
3.2. SIV immunization induced SIV gag-specific T cell responses in LN	  
             We next evaluated antigen-specific T cell responses by stimulation and 
intracellular cytokine staining. LN cells were stimulated in vitro with either SIV gag or 
CMV pp65 peptide pools and the percents of IL-2, TNF-α and IFN-γ-producing T cells 
were determined by polychromatic flow cytometry.  Data of the LN draining SIV gag 
immunization on Day 3, when the immune activation, as measured by IFN-γ mRNA was 
the highest, demonstrated a potent response to gag peptide stimulation according to IL-2, 
TNF-α and IFN-γ productions (Figure 3.3.2A and B). In contrast, the LN draining the 
CMV pp65 immunization on day 3, when stimulated by gag peptides, demonstrated no 
significant response (Figure 3.3.2A and B). 	  
	  
             SIV immunization-induced gag-specific CD8+ (Figure 3.3.2C) and CD4+ (Figure 
3.3.2D) T cell responses in LNs for all time points post immunization are summarized. 
As shown, the overall patterns for CD8+ and CD4+ T cell responses are similar in that an 
immediate and potent memory T cell response is induced on Day 3 post immunization, 
which is followed by a decline on Day 5 and a further decrease to the levels observed in 
60 day post immunization LNs (Figure 3.3.2C and D), consistent with the data obtained 
by measuring IFN-γ mRNA (Figure 3.3.1).	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              We next assessed the T cell subsets that mediated immunization-induced SIV 
gag-specific T-cell responses in Day 3 LN mononuclear cells. According to previous 
studies, CD28 and CD95 could be used to separate macaque T cells into naïve, central 
memory (CM) and effector memory (EM) populations. As shown in Figure 3.3.2E, the 
SIV-specific T cell responses were primarily mediated by central memory T cells in Day 
3 LN.  We then analyzed the polyfunctionality of SIV immunization-induced gag-specific 
T cells and found that both CD8+ and CD4+ SIV-specific T cell responses demonstrated a 
polyfunctional profile with the ability to produce 2 (IL-2/TNF-α, TNF-α/IFN-γ and IL-
2/IFN-γ) and 3 cytokines (IL-2/TNF-α/IFN-γ), simultaneously (Figure 3.3.2F). 	  
	  
Figure 3.3.2	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Figure 3.3.2. SIV immunization induced SIV gag-specific T cell responses in LNs. 
(A) Representative multi-color flow cytometry data for SIV gag-specific T cell responses 
in LN draining SIV-gag DNA (Top) or CMV-pp65 (Bottom) on Day 3 post 
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immunizations. LN mononuclear cells were stimulated with SIV-gag 15-mer overlapping 
peptide pools and stained intracellularly for IL-2, TNF-α and IFN-γ. The SIV-specific 
cytokine-producing CD4+ and CD8+ T cells were determined by multi-color flow 
cytometry.  (B) The percent of SIV gag-specific cytokine-producing CD4+ and CD8+ T 
cells in Day3 LN draining SIV gag and CMV pp65 immunization. (C, D) Summary for 
the percent of SIV gag-specific cytokine-producing CD8+ (C) and CD4+ (D) T cells in 
LNs on indicated days post immunization. (E) SIV gag-specific responses in LN were 
primarily mediated by central memory T cells. Macaque LN mononuclear cells were 
separated into naïve, central memory (CM) and effector memory (EM) cells according to 
CD28 and CD95 expressions. The individual cytokine expressios in these populations are 
shown. (F) Polyfunctionality of SIV-specific CD4+ and CD8+ T cell responses. The 
percent of CD4+ and CD8+ T cells able to produce 1, 2, and 3 cytokines is shown. 
	   	  
3.3. CMV immunization induced CMV pp65-specific T cell responses in LN	  
           We evaluated the CMV-specific T cell responses in a LN draining the CMV-pp65 
immunization. Unfortunately, due to cell viability and limited available cells, this was the 
only day we were able to analyze.  LN mononuclear cells on day 5 post immunization 
were in vitro stimulated with a CMV-pp65 peptide pool, and the pp65-specific cytokine-
producing T cells were assessed by multi-color flow cytometry. Compared to the LN 
draining SIV-gag immunization (Top panels, Figure 3.3.3A), the LN draining CMV-pp65 
immunization demonstrated significantly higher frequencies of IL-2-producing CD4+ and 
CD8+ T cells in response to pp65 peptides (Bottom panels, Figure 3.3.3A). The 
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comparison for the percent of IL-2, TNF-α and IFN-γ-producing CD4+ and CD8+ T cells 
in Day 5 LN draining SIV or CMV immunization is shown in Figure 3.3.3B.  
Figure 3.3.3 
 
 
Figure 3.3.3. CMV immunization induced CMV pp65-specific T cell responses in 
Day 5 LN.  (A) Multi-color flow cytometry data for CMV pp65-specific T cell responses 
in LN draining SIV-gag DNA (Top) or CMV-pp65 (Bottom) on Day 5 post 
	   77	   	   	  
immunizations. LN mononuclear cells were stimulated with CMV-pp65 15-mer 
overlapping peptide pools and stained intracellularly for IL-2, TNF-α and IFN-γ. (B) The 
percent of individual cytokine-producing CD4+ and CD8+ T cells compared between LNs 
draining SIV gag and CMV pp65 stimulated with CMV pp65 peptide pool. 
 
PART 4 
SIV- and CMV-specific T cell responses in peripheral blood	  
4.1. Staining for the SIV gag-specific tetramer p11C in peripheral blood	  
          After analyzing the immunization-induced local immunologic responses in 
draining LNs, we next sought to determine the systemic immune response in the 
peripheral blood of immunized macaques. PBMC were collected from macaques every 
two to four weeks throughout the experiment. We first determined the percent of 
circulating SIV-gag tetramer specific CD8+ T cells in PBMCs in all three macaques. 
PBMC were stained with SIV-gag p11c-MamuA*01 tetramer together with other lineage 
and viability markers. As shown, tetramer+ T cells were exclusively CD8+, demonstrating 
the specificity of SIV tetramer (Figure 3.4.1A). The kinetics for the number of tetramer+ 
SIV-specific CD8+ T cells in three animals are summarized in Figure 3.4.1B. Before SIV 
infection, no tetramer positive cells were detected. This was followed by potent increases 
after infection. The introduction of ART led to a dramatic decline of tetramer+ CD8+ T 
cells to lower levels through the end of experiment. During ART, some transient 
increases were observed for one animal (FH40), which was consistent with the transient 
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viral load blips seen in the same animal. After immunization, no significant increases 
were observed for the number of SIV-specific CD8+ T cells in the periphery of the 
macaques (Figure 3.4.1B).	  
Figure 3.4.1	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Figure 3.4.1. SIV gag-specific tetramer staining of PBMCs. (A) Representative 
tetramer staining and analysis for one PBMC sample from one macaque.  Single, live and 
CD3+ T lymphocytes were gated and the staining for tetramer and CD8 are shown. (B) 
Kinetics of tetramer+ SIV-specific CD8+ T cells in the studied rhesus macaques 
throughout the experiment. The results are expressed as percent of tetramer+ CD8+ T cells 
on indicated days post SIV infection for each animal. 	  
4.2. SIV- and CMV-specific T cell responses in PBMCs	  
	  	  	  	  	  	  	  	  	  	  We next determined the systemic response to immunization with SIV gag and CMV 
pp65 by analyzing peptide stimulated T cell responses. Macaque PBMCs collected before 
and after immunizations were in vitro stimulated with SIV-gag or CMV-pp65 peptide 
pools and cytokine-producing T cells were measured by multi-color cytometry. 
Representative multi-color flow cytometry histograms for SIV- and CMV-specific T cell 
responses (IL-2, TNF-α and IFN-γ) in PBMC at day 9 post immunization are shown 
(Figure 3.4.2A). CMV-specific responses were primarily mediated by CD8+ T cells 
producing the effector cytokines IFN-γ and TNF-α, whereas both CD4+ and CD8+, SIV-
specific T cells were induced primarily producing IL-2 with very little IFN-γ and TNF-α 
on day 9 (Figure 3.4.2A). 	  
	  
           The kinetics of immunization-induced SIV- and CMV-specific CD4+ and CD8+ T 
cell responses are summarized in Figure 3.4.2B. For the CD4+ T cell response, a transient 
SIV gag-specific, IL-2 producing response was observed at day 9 post immunization, that 
was not found on day 50 post immunization, whereas no significant CMV-specific CD4+ 
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T cell responses were detected at all studied time points. The gag-specific CD4+ T cells 
produced very little TNF-α and IFN-γ (Figure 3.4.2 B, Top).	  
	  
          Similar to SIV gag-specific CD4+ T cell responses, the SIV-specific CD8+ T cell 
response was transient and extinguished quickly with only an increase on day 9 post-
immunization.  The SIV-specific CD8+ T cells primarily produced IL-2 with very little 
TNF-α and IFN-γ productions. In contrast, CMV-specific CD8+ T cell responses 
demonstrated a long-lived, polyfunctional profile. A potent increase in CMV-specific 
CD8+ T cells was observed at day 3 post immunization with an average of 0.8% of CD8+ 
T cells able to produce TNF-α or IFN-γ. The TNF-α and IFN-γ-producing CMV-specific 
response was sustained until day 50 post-immunization. CD8+ and CD4+ T cell CMV-
specific T cells produced very little IL-2 (Figure 3.4.2B) 	  
	  
Figure 3.4.2	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Figure 3.4.2. SIV- and CMV-specific T cell responses in peripheral blood during 
immunization. (A) Representative multi-color flow cytometry data for SIV- and CMV-
specific T cell responses. PBMC before and after immunization were stimulated with SIV 
gag (Top) or CMV pp65 (Bottom) peptide pools and stained intracellularly for IL-2, 
TNF-α, and IFN-γ. The percentages of cytokine-producing CD8+ T cells were determined 
by multi-color flow cytometry. (B) The average of all animals for the percent of CD4+ 
and CD8+ T cells able to produce individual cytokines (IL-2, TNF-α or IFN-γ) is shown 
and compared between SIV- and CMV-specific responses.	  
	  
4.3. T cell subsets that mediate SIV- and CMV-specific T cell responses in PBMC	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  We also assessed the T cell subsets (naïve, central memory, and effector memory) 
that mediated the antigen-specific T-cell responses in PBMC post immunization. Using 
the Day 9 PBMC when both SIV- and CMV-specific T cell responses were highest, we 
analyzed individual cytokine production in naïve, central memory, and effector memory 
T cell subsets. The SIV-specific IL-2-producing response was mediated by effector (EM) 
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and central memory (CM) T cells (Figure 3.4.3A). In contrast, the CMV-specific TNF-α 
and IFN-γ- responses were primarily mediated by effector memory (EM) T cells (Figure 
3.4.3B).	  
	  
Figure 3.4.3	  
	  
	   83	   	   	  
	  
Figure 3.4.3. Analysis of T cell subsets mediating the antigen-specific T cell 
responses in PBMC.  Macaque PBMC were separated into naïve, central memory (CM) 
and effector memory (EM) cells according to CD28 and CD95 expression. The individual 
cytokine expression in these populations for SIV-specific (A) and CMV-specific (B) 
responses are shown. 
	  
4.4. Increased PD-1 expression in SIV-specific CD8+ T cells 	  
           T cell exhaustion often occurs and prevents optimal viral control during chronic 
infection 17. An important role of the PD-1:PD-L1 pathway has been reported for CD8+ T 
cell exhaustion during chronic viral infection 11. We co-stained the PBMC for the SIV-
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gag tetramer p11c and PD-1 to determine the differential expression of PD-1 on SIV-
specific and total CD8+ T cells. As seen in a representative histogram of tetramer-PD-1 
staining, PD-1 was significantly upregulated in tetramer+ CD8+ T cells compared to 
tetramer negative CD8+ T cells (Figure 3.4.4A). The PD1 expression in PBMC during the 
course of SIV infection and immunization was analyzed, and it was observed that PD1 
expression on SIV-specific CD8+ T cells was significantly higher than tetramer negative 
CD8+ T cells for all time points studied, suggesting exhaustion of SIV-specific CD8+ T 
cells, which was not reversed by ART and immunization (Figure 3.4.4B). 	  
	  
Figure 3.4.4	  
	  
Figure 3.4.4. PD-1 expression on SIV-specific and non-SIV specific CD8+ T cells in 
macaque PBMC.  (A) Representative flow cytometry histogram data for mean 
fluorescence intensity (MFI) of PD-1 staining on SIV-specific and tetramer negative 
CD8+ T cells. (B) PD-1 expression on SIV-specific and tetramer negative CD8+ T cells in 
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PBMC collected on indicated days post SIV infection. The results are shown as the 
averge of mean fluorescence intensity (MFI) of PD1 staining for two monkeys.	  
	  
PART 5	  
Immunization induced virologic responses in draining LNs 
5.1. SIV immunization selectively stimulates transient activation of viral replication 
in draining LNs 
  ART can efficiently control viral replication but fails to eradicate virus due to the 
establishment of long-lived reservoirs 126. It has been demonstrated that a low level of 
viral production continues even in the setting of the most potent antiviral regimens 43, 70, 
122, but the source of this virus is not believed to be from new infection of cells 32, 84, 122. 
Total RNA from LNs draining either SIV gag or CMV pp65 immunizations was analyzed 
by real-time PCR for multiple SIV viral RNA transcripts, including unspliced, doubly 
spliced, and singly-spliced RNA119. As preimmunization control LNs could not be 
obtained, LN biopsies from both sides, draining either gag or pp65, from each macaque 
were collected. No significant differences in levels of unspliced and spliced RNA 
transcripts were observed comparing right to left side for each animal. Thus, this time 
point was chosen for comparisons.  Copy numbers of SIV RNA were normalized to 
GAPDH RNA and the results for each time point following immunization are shown as 
fold change relative to RNA collected at 60 days post immunization (Figure 3.5A, B, C). 
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             The levels of doubly spliced SIV RNA viral transcripts in LNs draining the SIV 
gag immunization demonstrated a 3.6-fold increase at day 3, which was sustained until 
day 11 post immunization when a 6.5-fold increase was observed. Minor increases in 
copies of doubly spliced SIV RNA were observed in LNs draining the CMV pp65 
immunization (Figure 3.5A).  The levels of singly spliced viral transcripts demonstrated a 
similar increase in RNA in LNs draining the SIV gag immunization with an 11.8-fold 
increase at day 11 (Figure 3.5B). Unspliced SIV RNA levels were determined and an 8.3-
fold increase was observed at day 7 (Figure 3.5C). The percent of CD4+ T cells in LN 
mononuclear cells did not differ between LNs draining SIV gag and CMV pp65 
immunizations, suggesting that the increase in viral replication was not due to differential 
CD4+ T cell migration to the LN draining gag antigen, although we cannot rule out that a 
larger fraction of cells that trafficked to the gag LN were infected and expressing viral 
RNA transcripts.    
 
Figure 3.5 
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Figure 3.5 Quantitation of multiple SIV viral RNAs in LNs. Total RNA extracted 
from LN mononuclear cells draining either SIV gag or CMV pp65 were subject to real-
time PCR with specific primers and probes for quantiation of SIV doubly spliced RNA 
(A), singly spliced RNA (B) and unspliced RNA (C). Copy numbers of SIV RNAs were 
normalized to macaque GAPDH and the results for each time point following 
immunization were shown as fold change relative to RNA collected on day 60 post 
immunization as a no vaccine control. The comparisons were made between LNs from 
the same animal at the same time on indicated days with a * indicating a p < 0.05).   
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5.2. No increases viral load were observed in peripheral blood post immunizations  
              A transient activation of SIV viral replication in LNs draining the SIV gag 
immunization was observed beginning at day 3 that returned to baseline at day 14-post 
immunization (Figure 3.5). We next sought to determine whether this transient viral 
replication could be seen in peripheral blood. The peripheral viral loads prior to and after 
antigen immunization in all animals are shown in Table 5. Except for a transient viral blip 
in one animal at day 31 post-immunization (270 copies/µl) that returned to undetectable 3 
weeks later, no increase in viral loads that could be attributed to SIV gag immunization 
induced viral replication was detected. The data suggests that in the setting of potent anti-
viral suppression, SIV antigen immunization activated viral replication was transient and 
restricted to draining LNs without spread to the periphery. 
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Discussion 
 A biphasic destruction of CD4+ T cells is observed in HIV infection, with a 
massive loss of CD4+ T cells during early infection and a subsequent progressive loss 
during the chronic stage of infection 47, 125. Retroviral suppression by ART results in an 
increase in peripheral CD4+ T cell counts and functional reconstitution of CD4+ T cell 
responses to many common antigens 8, 83, but HIV-specific CD4+ T cell responses remain 
deficient 129. To identify potential mechanisms for this persistent loss of HIV-specific 
CD4 immune function, we studied ART-treated, chronic SIV and CMV infected rhesus 
macaques136, and observed 1) that both SIV and CMV antigen immunizations could 
induce immune activation and antigen-specific T cell responses in draining LNs. 2) In 
peripheral blood, the CMV-specific response induced by immunization was potent and 
sustained, whereas the SIV-specific response was transient and extinguished quickly. 3) I 
demonstrate that SIV antigen immunization induces transient activation of SIV viral 
replication that was not observed with CMV pp65 immunization. The data is consistent 
with a hypothesis that SIV antigens induce viral replication that leads to depletion or 
dysfunction of antigen specific cells leading to a reduction in the strength and longevity 
of the response. 
 
 Pathogenic SIVmac 251 infection of rhesus macaques has been well described as 
one of the preferred experimental models for studying HIV pathogenesis92. The macaques 
in our study were inoculated with SIVmac251 and all established primary infection with 
typical viral replication dynamics68, 114, 143. Similar to the observations for HIV-1 infected 
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individuals where ART can sustain suppression of plasma viremia to undetectable levels 
120, all macaques in our study demonstrated uniform responsiveness to ART (Figure 
3.2A). We observed that the macaques also exhibited a sustained increase in peripheral 
CD4+ T cell numbers above 500 cells/µl after PMPA and D4T treatment, demonstrating 
the establishment of suppressed viral replication and recovered CD4+ T cell counts 
observed in HIV-infected subjects treated with ART during chronic infection. 
 
 Expression of particular MHC class I alleles are associated with different rates of 
disease progression in humans and macaques 23, 24, 81, 110, 171. In our study, all three rhesus 
macaques expressed Mamu A*01 to control for an MHC effect on viral immune 
responses and disease progression as well as to aid in the measurement of immune 
responses. The advantage of selecting one haplotype is that the animals studied will have 
similar responses to infections and immunizations, which enhances our ability to make 
conclusions with a small number of animals. Indeed, limited variation in viral replication 
dynamics were observed across monkeys after primary infection and prior to initiation of 
ART (Figure 3.2A).   
 
  The ability of therapeutic immunization to elicit SIV-specific immune responses 
in SIV-infected rhesus macaques during ART and its virologic benefits have been 
investigated primarily in peripheral blood using DNA immunization 57, 150, 157, 173 and 
other systems 42, 69, 96. After release from ART, variable immunologic and virologic 
benefits were reported from no control 173, temporal control 69, to long-lasting control 96. 
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In this study, using CMV infection as a control, we investigated the immunologic and 
virologic consequences of immunization with SIV antigen in chronic SIV and CMV co-
infected, ART treated rhesus macaques. All the comparisons between LNs at each time 
point were from the same animal collected at the same time, thus allowing me to use each 
animal as its own control and reach a statistically significant result. Also, my study 
focused on the local responses in draining LN where antigen-specific T cell responses 
and viral replication occurs, rather than systemic responses in peripheral blood. In 
addition, I chose a range of days post-immunization covering the early activation of 
memory T cells and generation of effector responses. My data show that both SIV and 
CMV antigen immunizations induced significant immune activation and antigen-specific 
T cell responses in draining LNs and peripheral blood. The CMV-specific response was 
sustained in PBMC with a rapid onset of cytokine producing CD8+ T cells 3 days post 
immunization, which was maintained at day 50-post immunization.  However, the 
immunization induced SIV-specific T cell response was transient and extinguished 
quickly in blood. Of interest, a study that repeatedly immunized macaques with long-
standing ART-treated SIVmac251 infection induced stronger SIV-specific CD4+ and 
CD8+ T cell responses in blood 148. This study used the MVA viral vector and delivered 
three immunizations, whereas in our study, only single gag DNA immunization was used.  
 
             In addition, SIV- and CMV-specific T cell responses in PBMC demonstrated 
different functional profiles. Both CD4+ and CD8+ SIV-specific T cells were transiently 
detected and produced mainly IL-2 with very little TNF-α and IFN-γ, whereas the CMV-
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specific responses, primarily mediated by CD8+ T cells, exhibited high TNF-α and IFN-γ 
production but very little IL-2. It was previously shown that the response patterns of 
antigen-specific CD4+ T cells change as they mature. More mature cells infrequently 
produced IL-2 and produced effector cytokines and chemokines 25. My results 
demonstrate that the SIV-specific IL-2-producing T cell responses were central and 
effector memory T cells, whereas the CMV-specific TNF-α and IFN-γ-producing 
responses were almost exclusively mediated by the more mature effector memory T cells. 
My results suggests that in peripheral blood, in addition to being present for 50 days, the 
CMV-specific T cells demonstrated a more polyfunctional profile and more mature 
phenotype, which is in agreement with a study showing that in HIV and CMV co-
infected individuals, the CMV-specific CD4+ T cells were able to produce increased β-
chemokines (MIP-1α and MIP-1β), which was associated with a more mature phenotype 
and decreased susceptibility to HIV infection, compared to HIV-specific CD4+ T cells 26. 
The in vivo relevance of such IL-2 producing SIV-specific T cells is not clear in terms of 
protective cellular immunity and susceptibility to viral infection as potential new targets, 
but my data suggests that they are rapidly lost.  
 
            The progressive loss of effector function in the setting of chronic vial infections 
has been associated with the upregulation of programmed death 1 (PD1)11. In HIV/SIV 
infection, increased expression of PD1 is shown to correlate with CD8+ T cell exhaustion 
and failure of immune control, which is reversible both in vitro and in vivo with PD1 
blockade 40, 147, 152. In our study, we monitored PD1 expression on SIV-specific and 
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tetramer negative CD8+ T cells and found that PD1 expression on SIV-specific CD8+ T 
cells were significantly higher than on tetramer negative CD8+ T cells throughout the 
entire experiment, which could not be markedly reversed by ART and immunization 
(Figure 3.4.4). This strongly indicated the selective exhaustion for SIV-specific CD8+ T 
cells during acute and chronic SIV infection, consistent with a study by Petrovas C et al	  
123.	    
 
  HIV-specific CD4+ memory T cells are preferentially infected by HIV, carrying 
approximately 2- to 5-fold more viral DNA than total memory cells 46. It has also been 
shown that even during the most potent regimens of retroviral suppression, the presence 
of virus could be measured by some ultrasensitive assays 43, 70, 122. These findings raise 
the concern that immunizations that induced HIV/SIV-specific T cells may accelerate 
viral replication even in the setting of potent ART. In support of this hypothesis, a 
vaccine that induced poor CD8+ T cell and neutralizing antibody responses led to 
enhanced SIV replication after challenge that was associated with enhanced CD4+ T cell 
proliferation 142. We hypothesized that during an HIV-specific response, activation of 
HIV-specific CD4+ T cells, which bear higher amounts of latent virus, results in 
activation of viral replication in the LN leading to suppression of CD4+ T cells and the 
HIV-specific responses through multiple mechanisms, whereas a non-HIV antigen-
specific response activates little viral replication allowing efficient expansion of the 
response.  
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 We used a naturally CMV infected, SIVmac251 infected and ART treated during 
chronic infection rhesus macaque model to study the effects of immune stimulation using 
HIV gag and CMV pp65 antigens. The studies concentrated on the early immune and 
viral responses in draining lymphoid organs. Both antigen immunizations were able to 
induce transient immune activation and generated antigen-specific T cell responses in 
draining LNs, but the SIV gag immunization also induced significant viral replication. 
The SIV response extinguished quickly in peripheral blood, while the CMV response was 
sustained. Our data suggests that SIV antigens, as part of a vaccine or potentially as part 
of the normal immune response to the virus, leads to T cell stimulation with subsequent 
viral replication that leads to an impairment in the immune response to the virus. It is 
possible that this mechanism is responsible for the observation that in progressing HIV 
infected subjects; CD4-specific responses to HIV antigens are lost early in infection and 
are difficult to restore or induce. 
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CHAPTER 4 
Thesis conclusions and future research directions 
 
Thesis conclusions and implications 
              In the first part of my thesis, using an in vitro system modeling the interaction 
between HIV Env and CD4+ T cells, I further characterize that Env protein, when 
delivered as a vaccine and expressed on APCs or non-APCs, present on free circulating 
virions, or as expressed by HIV-infected cells could induce inhibition of antigen-
stimulated CD4+ T cell activation and proliferation, which is dependent of CD4 binding 
and independent of coreceptor binding. The inhibition is not characterized as apoptosis, 
anergy or cell death. These Env exposed CD4+ T cells can phosphorylate key signaling 
mediators including MAPK, AKT, and STAT5a in a normal fashion but fail to fully up-
regulate activation markers such as CD69, HLA-DR, and CD25. Treg cells are not 
functionally involved in Env-induced inhibition of CD4+ T cell activation and exposure 
of PBMC to Env neither changes the frequency nor the suppressive activity of Tregs.  
Using this data, I established a hypothesis, which suggests a mechanism for the 
generation of poor responses to HIV vaccines that contain Env. This hypothesis has 
implications for the development of novel HIV Env vaccine candidates with improved 
immunogenicity.  
            In the second part of my thesis, I employed an in vivo model system to further 
analyze HIV suppression of CD4+ T cell antigen-specific immune responses. I 
demonstrate that in draining lymph nodes of chronically SIV and CMV co-infected 
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rhesus macaques during ART, both SIV- and CMV-immunization could induce immune 
activation and antigen-specific memory T cell responses. The SIV-specific T cell 
responses are polyfunctional with the production of multiple cytokines (IL-2, TNF-α and 
IFN-γ) and primarily mediated by central memory T cells. I further track the 
immunization-induced antigen-specific systemic responses in peripheral blood, and 
demonstrate that SIV-specific T cell responses were transient and extinguished quickly in 
blood. The SIV-specific responses in blood primarily produced IL-2 and was mediated by 
multiple T cell subsets, effector and central memory. In contrast, the CMV-specific T cell 
responses were sustained in PBMC with a rapid onset of CD8+ T cells able to produce 
high levels of TNF-α and IFN-γ with very little IL-2, and was mainly mediated by more 
mature effector memory cells. The SIV immunization led to a transient activation of viral 
replication in draining LNs, without spread to the periphery. My results may have some 
potentially important implications for HIV infection and immunization in humans.  First, 
the immune activation associated with HIV immunization during ART stimulates 
transient viral replication in draining LNs. Second, the transient viral replication leads to 
impairment of the HIV-specific response by multiple mechanisms resulting in an 
impaired HIV-specific systemic T cell response. In applying these findings to the 
induction of HIV-specific immune responses in the setting of any viral replication, I 
propose that the generation of HIV-specific CD4+ T cell responses leads to elevated local 
viral replication with resulting loss of HIV-specific immune responses. These findings 
demonstrate a potential mechanism for the failure of progressing subjects to develop an 
HIV-specific CD4+ T cell response.  
	   97	   	   	  
Ongoing experiments and future directions 
            In addition to the mononuclear cells prepared from the LN for immunologic and 
virologc analysis as described in my thesis, fixed LN tissues were also prepared for in 
situ analysis. We are currently working with Dr. Ashley Haase’s laboratory to study these 
fixed LN tissues using technologies such as in situ hybridization, in situ 
immunohistochemitry including tetramer specific staining, and quantitative image 
analysis to visualize in situ viral replication induced by SIV gag immunization and the 
host’s cellular immune responses in LN tissues draining SIV and CMV immunization. In 
particular, we are interested in further dissecting the mechanisms for the inhibition of 
HIV-specific CD4+ T cell immunity, including; 1) SIV- and CMV-induced apoptosis; 2) 
regulation of Treg cells and other potential inhibitory molecules (i.e. PD-1); and 3) viral 
replication associated with cell type, activation status, and antigen-specificity.  
 
             Future interesting research would include: 1) investigation of TCR or cytokine 
signaling cascades by Env or virus in CD4+ T cells to further dissect the molecular 
mechanisms involved in inhibition of CD4+ T cell activation; 2) SIV rhesus macaque 
studies with a larger number of monkeys. Preliminary results obtained in my thesis 
demonstrate that in chronic SIV infection during ART, immunization-induced systemic 
SIV-specific T cell responses compared to CMV-specific T cell responses differ in being 
more transient and have a different profile of cytokine expression, high IL-2, but very 
little TNF-α and IFN-γ production. Interesting questions could be asked about this 
difference in a larger SIV macaque study. Are these IL-2 producing CD4+ and CD8+ T 
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cell responses protective? Or, in contrast, do these IL-2 producing activated T cells serve 
as targets for viral infection or activation of latent virus? Finally, a number of questions 
were raised by my pilot macaque study and data worthy of investigation in a larger trial 
was identified. First, for time points studied, I would have multiple LN samples from 
different animals draining SIV and CMV immunization. This would give statistical 
significance for a group instead of significance for the comparison in the same animal. 
Second, according to our preliminary results, I focus studies on Day 3 and Day 5 when 
the immunization-induced local responses are highest. I would also add a time point prior 
to day 3 and reduce the number of time points after day 5. This will allow more LN 
samples for analysis without greatly increasing the number of animals needed. Moreover, 
if more cryopreserved LN mononuclear cells are available, cells will be analyzed for 
infection, apoptosis and exhaustion associated with cell type and antigen-specific 
immune activation. Cells could also be sorted into different subsets, such as DCs, 
macrophages, and CD4+ and CD8+ T cells and these cells will be analyzed for the extent 
of infection and viral integration and effector functions. This may allow for the 
identification of the cell types that are replicating virus in response to SIV immunization. 
I would also add studies to determine if the loss of the SIV-specific response is an active 
process. This could be done by analyzing apoptosis markers on tetramer positive cells. 
The addition of a CMV specific tetramer would allow a more complete analysis and I 
would work with Dr. Peter Barry at UC Davis to try and develop one.  The analysis of 
additional LN samples will also allow a more thorough investigation of the T cell 
responses to antigen. 
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